UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September 2020

 

ZHONGCHAO INC.

(Translation of Registrant’s name into English)

 

Nanxi Creative Center, Suite 218

841 Yan’an Middle Road

Jing’An District, Shanghai, China 200040

Tel: 021-32205987

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

CONTENTS

 

As previously disclosed in the Registration Statement on Form F-1 (File No. 333- 333-234807) filed with the Securities and Exchange Commission on January 10, 2020 (the “Registration Statement”), Zhongchao Inc. (the “Registrant”) conducts its operations through its variable interest entity (“VIE”), Zhongchao Medical Technology (Shanghai) Limited (“Zhongchao Shanghai”), a limited liability company established under the laws of the China, which is controlled through VIE arrangements in lieu of direct equity ownership by the Registrant or any of its subsidiaries. Such VIE arrangements consist of a series of six agreements (collectively, the “Original VIE Arrangements”), which were signed on August 14, 2019, which were filed as a part of the exhibits to the Registration Statement. 

 

Pursuant to the Equity Interest Pledge Agreement among Beijing Zhongchao Zhongxing Technology Limited (“Zhongchao WFOE”) and Zhongchao Shanghai and its shareholders dated as of August 14, 2019, Zhongchao Shanghai was 44.91% owned by Mr. Weiguang Yang, the Chief Executive Officer and Chairman of the Board of the Registrant, and 13.87% owned by Shanghai Xingzhong Investment Management LP, Ltd., the general partner of which is Mr. Yang (“Shanghai Xingzhong”), 12.68% owned by Shanghai Haoxi Investment Management LP., Ltd., 6.25% owned by Yantai Hanfujingfei Investment Centre (LP), 6.25% owned by Ningbo Meishang Bonded Port Area Mijia Equity Investment LP, Ltd., with the remaining equity interests owned by certain minority shareholders.

 

On August 1, 2020, all shareholders of Zhongchao Shanghai, except Mr. Yang and Shanghai Xingzhong, decided to withdraw their capital contribution from Zhongchao Shanghai (the “Capital Reduction”). Given the effect of the Capital Reduction, Mr. Yang became the 76.4% shareholder of Zhongchao Shanghai with the remaining equity interests held by Shanghai Xingzhong. The Registrant was advised by its PRC counsel that the Original VIE Arrangements shall be terminated, except for the Master Exclusive Service Agreement by and between Zhongchao WFOE and Zhongchao Shanghai dated as of August 14, 2019, to reflect the Capital Reduction. On September 10, 2020, Zhongchao WFOE, and Zhongchao Shanghai, and its shareholders signed a confirmation agreement to confirm that the Original VIE Agreements have been terminated because of the Capital Reduction.

 

Accordingly, on September 10, 2020, to clarify the legal effect of the Capital Reduction and to sustain the effective control over Zhongchao Shanghai by the Registrant, Mr. Yang and Shanghai Xingzhong, as the shareholders of Zhongchao Shanghai, signed a series of VIE agreements with Zhongchao WFOE, the terms of which are substantially the same as those of the Original VIE Arrangements except the number of shareholders of Zhongchao Shanghai reduced to two (the “New VIE Agreements”). Upon entry into the New VIE Agreements, the Original VIE Agreements, except for the Master Exclusive Service Agreement, were expired.

 

The board of directors of the Registrant approved and ratified the New VIE Agreements. The Registrant does not expect any negative impact of these New VIE Agreements on its operation. The New VIE Agreements enable Zhongchao WFOE and the Registrant to keep the effective control over Zhongchao Shanghai. A copy of the relevant agreements are attached hereto and are incorporated herein by reference.

 

Exhibits:

 

10.1   Equity Interest Pledge Agreement among Beijing Zhongchao Zhongxing Technology Limited and Zhongchao Medical Technology (Shanghai) Corp. and its shareholders dated as of September 10, 2020
     
10.2   Proxy Agreement and Power of Attorney among Beijing Zhongchao Zhongxing Technology Limited and Zhongchao Medical Technology (Shanghai) Corp. and its shareholders dated as of September 10, 2020
     
10.3   Spouse Consent Letters of the spouse of each married shareholder of Zhongchao Medical Technology (Shanghai) Corp. dated as of September 10, 2020
     
10.4   Business Cooperation Agreement among Beijing Zhongchao Zhongxing Technology Limited and Zhongchao Medical Technology (Shanghai) Corp. and its shareholders dated as of September 10, 2020
     
10.5   Exclusive Option Agreement among Beijing Zhongchao Zhongxing Technology Limited and Zhongchao Medical Technology (Shanghai) Corp. and its shareholders dated as of September 10, 2020
     
10.6   Confirmation Agreement among Beijing Zhongchao Zhongxing Technology Limited and Zhongchao Shanghai and its shareholders dated as of September 10, 2020.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  Zhongchao Inc.
     
  By: /s/ Weiguang Yang
  Name:  Weiguang Yang
  Title:  Chief Executive Officer

 

Date: September 16, 2020

 

 

2

 

Exhibit 10.1

 

股权质押协议

 

EQUITY INTEREST PLEDGE AGREEMENT

 

本股权质押协议(“本协议”)由以下各方于2020年 9 10 日在上海订立:

 

This Equity Interest Pledge Agreement(this “Agreement”)is entered into in Shanghai as of September 10th , 2020 by and among the following parties:

 

(1) 质权人(Pledgee):

 

北京众巢众行科技有限公司(“外商独资企业”),一家根据中华人民共和国(“中国”)法律在中国上海注册成立的外商独资企业; 

 

Beijing Zhongchao Zhongxing Technology Co.,Ltd. (the “WFOE”), a wholly foreign-owned enterprise registered in Beijing, the People’s Republic of China (“China” or “PRC”), under the laws of China;

 

(2)       出质人(Pledgor):

 

杨伟光,身份证号362227198206170314,为众巢医学科技(上海)有限公司(“众巢医学”)的股东;

 

Weiguang Yang, No. 362227198206170314, shareholder of Zhongchao Medical Technology (Shanghai) Co., Ltd.(“Zhongchao”) ;

 

上海行众投资管理合伙企业(有限合伙),统一信用代码913101143584694449,为众巢医学的股东;

 

Shanghai Xingzhong Investment Management LP, Ltd. , No. 913101143584694449, shareholder of Zhongchao

 

每一位在上文列明的出质人单独称为 “各股东”,合称为“股东”。

 

Each of the pledgors listed above (each, a “Shareholder” and collectively, the “Shareholders”)

 

(3)       公司(Company):

 

众巢医学科技(上海)有限公司(“众巢医学”),一家根据中国法律在中国上海注册成立的内资公司

 

Zhongchao Medical Technology (Shanghai) Co., Ltd. (“Zhongchao”), a domestic company registered in Shanghai, China, under the laws of China

 

(以上外商独资企业、每一位股东和众巢医学单独称为“一方”,合称为“各方”)。

 

the WFOE, each of the Shareholders and Zhongchao Yixue, a “Party”, and collectively the “Parties”).

  

1 / 16

 

 

序言

 

RECITALS

 

(A) 鉴于,股东持有众巢医学100%的股权;

 

WHEREAS, the Shareholders hold 100 % equity interest in Zhongchao.

 

杨伟光持有众巢医学出资额人民币9,701,100元,占总股本的76.4%;

 

Weiguang Yang holds 76.4% of the total equity interest in Zhongchao;

 

上海行众投资管理合伙企业(有限合伙)持有众巢医学出资额人民币2,997,000元,占总股本的23.6%;

 

Shanghai Xingzhong Investment Management LP, Ltd. holds 23.6% of the total equity interest in Zhongchao;

 

(B) 鉴于,外商独资企业和众巢医学于2019年8月14日签署了一份《独家服务总协议》(“服务协议”);

 

WHEREAS, the WFOE and Zhongchao entered into a master exclusive service agreement dated August 14, 2019 (the “Service Agreement”)

 

(C) 鉴于,外商独资企业、众巢医学和股东于2020年 9 月 10 日签署了一份《业务合作协议》(“业务合作协议”);

 

WHEREAS, the WFOE, Zhongchao and the Shareholders entered into a business cooperation agreement dated September 10th ,2020 (the “Business Cooperation Agreement”);

 

(D) 鉴于,外商独资企业、众巢医学和股东于2020年 9 月 10 日签署了一份《独家购股权协议》(“独家购股权协议”,与服务协议和业务合作协议以及由股东、众巢医学以及外商独资企业共同签订的各协议一同合称为“主协议”);

 

WHEREAS, the WFOE, Zhongchao and the Shareholders entered into an Exclusive Option Agreement dated September 10th ,2020(the “Exclusive Option Agreement”, together with the Service Agreement and the Business Cooperation Agreement and the agreements to be executed among the Shareholders, Zhongchao and the WFOE from time to time, the “Principal Agreements”);

 

(E) 鉴于,外商独资企业要求股东无条件和不可撤销地将其持有的众巢医学100%股权质押给外商独资企业,作为对股东、众巢医学履行主协议项下义务的担保,且股东同意提供该担保。

 

WHEREAS, the WFOE requests the Shareholders to pledge 100% equity interest of Zhongchao they own to the WFOE unconditionally and irrevocably, as security for the performance of the obligations by the Shareholders and Zhongchao under the Principal Agreements, and the Shareholders agree to provide such security.

 

2 / 16

 

 

(F) 有鉴于此,基于本协议包含的各项前提、声明、保证、承诺和约定,各方愿意受其法律约束,并达成如下约定:

 

NOW, THEREFORE, in consideration of the premises and the representations, warranties, covenants and agreements herein contained, and intending to be legally bound hereby, the Parties hereby agree as follows:

 

协议

 

AGREEMENT

 

1. 主协议

 

Principal Agreements

 

本协议各方认可并确认,本协议项下质押担保的主协议包括,服务协议、业务合作协议、独家购股权协议,以及由股东、众巢医学以及外商独资企业不时签订的各协议。

 

All Parties hereto acknowledge and confirm that the Principal Agreements for which the security of pledge is provided hereunder include the Service Agreement, the Business Cooperation Agreement, the Exclusive Option Agreement and the agreements to be executed among the Shareholders, Zhongchao and the WFOE from time to time.

 

2. 质押

 

The Pledge

 

股东同意无条件和不可撤销地将其持有的全部众巢医学股权(包括为该等股权支付的任何利息或股息)质押给外商独资企业(“质押股权”),作为对股东、众巢医学履行主协议项下所有、一切义务的担保(“质押”)。本协议各方同意,以1269.81万元人民币(“初始登记金额”)作为本协议签订日主协议项下义务的估值进行初始质押登记。在主合同及本合同有效期内后续期限内,外商独资企业在任何时候有权以任何理由要求任一名股东对初始登记金额进行调整,所有股东应当根据外商独资企业之要求及时完成调整。

 

Each Shareholder agrees to pledge all of the equity interest of Zhongchao that it owns, including any interest or dividend paid for such equity interest (the “Pledged Equity Interest”) to the WFOE unconditionally and irrevocably, as a security for the performance of any and all obligations by the Shareholder and Zhongchao under the Principal Agreements (the “Pledge”). Parties agree to use RMB 12,698,100 (the “Initial Registration Amount”)as the estimated value of the obligations by the Shareholder and Zhongchao under the Principal Agreements for initial registration purpose. During the term of the Principal Agreements or this Agreement, the WFOE has the rights to request all of the Shareholders to amend the Initial Registration Amount for any reasons, and all Shareholders shall promptly make such adjustments as requested.

 

3 / 16

 

 

3. 质押范围

 

The Scope of Pledge

 

本协议项下的质押所担保的范围包括股东、众巢医学在主协议下的全部欠款、义务和债务、为行使债权人权利和质权而发生的费用、外商独资企业因股东和/或众巢医学的任何违约事件(定义见第8.1条)而遭受的全部直接、间接、衍生损失和可预计利益的丧失(该等损失的金额的依据包括但不限于外商独资企业合理的商业计划和盈利预测、众巢医学在服务协议项下应支付的服务费用)和任何其他相关费用(“担保债务”)。

 

为避免疑义,股东出资金额或初始登记金额与质押范围或担保债务无关;质押范围、实际担保债务的金额完全不受股东出资金额或初始登记金额的任何限制;任何股东不得以任何方式、任何理由、通过任何程序主张质押范围或担保债务应当受到出资金额或初始登记金额的任何限制。

 

The Pledge under this Agreement shall cover all indebtedness, obligations and liabilities of the Shareholders and Zhongchao under the Principal Agreements, any fees for exercising the creditor's rights and the Pledge, all the direct, indirect and derivative losses and losses of anticipated profits, suffered by the WFOE, incurred as a result of any Event of Default (as defined in Section 8.1) (the amount of such loss shall be calculated in accordance with the reasonable business plan and profit forecast of the WFOE and the consulting and service fees payable to the WFOE under the Service Agreement, among other factors) and any other related expenses (the “Secured Indebtedness”).

 

For the avoidance of doubt, the amount of the Shareholders’ capital contribution or the Initial Registration Amount is in no event related to the scope of the Pledge; the scope of the Pledge or the Secured Indebtedness shall not in any way be limited by the amount of the Shareholders’ capital contribution or the Initial Registration Amount; no Shareholder should through any means, use any reasons or pursue any procedure to claim or attempt to claim that scope of the Pledge or the Secured Indebtedness shall in any way be limited by the amount of the Shareholders’ capital contribution or the Initial Registration Amount.

 

4. 质押期限

 

The Term of Pledge

 

4.1 为办理质押登记之目的,初始质押登记记载的有效期应为20年,该期限届满后,根据外商独资企业的要求,股东应无条件配合外商独资企业办理质押登记有限期的展期登记手续。质押期限届满后,除非(1)协议各方一致书面同意终止本协议,或(2)主协议被履行完毕且令外商独资企业满意,或(3)直至所有主协议有效期已经届满或已经终止,否则质押将一直有效。

 

For purpose of equity interest pledge registration, the term of initial pledge registration shall be 20 years. After the expiration of the term of initial pledge registration, the WFOE may at its sole discretion require the Shareholders to extend the term of the equity interest registration. Unless (i) the Parties all agree to terminate this Agreement; (ii) the Principal Agreements have been fulfilled to the satisfaction of the WFOE; or (iii) all of the Principal Agreements have expired or been terminated, the Pledge shall be valid.

 

4 / 16

 

 

4.2 在质押有效期内,如果股东或众巢医学未能履行主协议项下各自的义务,外商独资企业有 权根据本协议规定处置全部或部分质押股权。

 

During the term of the Pledge, in the event that either the Shareholders or Zhongchao fail to perform any of their respective obligations under the Principal Agreements, the WFOE shall have the right to dispose of the Pledged Equity Interest entirely or partially in accordance with the provisions of this Agreement.

 

4.3 外商独资企业有权收取质押股权在质押期间内产生的股息。

 

The WFOE shall have the right to collect dividends generated by the Pledged Equity Interest during the term of the Pledge.

 

5. 登记

 

Registration

 

5.1 众巢医学应(1)在本协议签署之日,在众巢医学股东名册中登记质押,并向外商独资企业提供该股东名册,且(2)在本协议签署后尽可能最短的时间内(任何情况下不得晚于本协议签署后六十(60)个工作日),向适格的工商行政管理局(“工商局”)提交质押登记申请,及取得相关的证明文件。股东和众巢医学应提交和完成中国法律、法规和相关工商局要求的所有文件和程序,以确保本协议下的质权有效设立并可强制执行。

 

Zhongchao shall (1) on the date of execution of this Agreement, record the Pledge in the shareholders’ register of Zhongchao and provide the shareholders’ register to the WFOE, and (2) submit an application to the relevant administration for industry and commerce (the “AIC”) for the registration of the Pledge as soon as practicable following the execution of this Agreement (no later than sixty (60) business days after the execution of this Agreement) and obtain evidencing documents of such registration. The Shareholders and Zhongchao shall submit all necessary documents and complete all necessary procedures, as required by PRC laws and regulations and the AIC, to ensure that the Pledge shall be duly established and fully enforceable.

 

5.2 不限于本协议中的任何规定,在质押期间,众巢医学的股东名册原件应由外商独资企业或其指定人保管。

 

Without limitation to any provision of this Agreement, during the term of the Pledge, the original shareholders’ register of Zhongchao shall be in the custody of the WFOE or its designated person.

 

5.3 如获外商独资企业事先同意,股东可以增加对众巢医学的出资,但前提是股东对众巢医学的任何出资都要受本协议规定之约束。众巢医学应根据本第5条规定立即变更其股东名册,并于五(5)个工作日内向工商局进行质押的变更登记。

 

With the prior consent of the WFOE, the Shareholders may increase their capital contribution to Zhongchao, provided that any capital contribution by the Shareholders to Zhongchao shall be subject to this Agreement. Zhongchao shall immediately amend the shareholders’ register and register the change to the Pledge with the AIC pursuant to the provisions in this Section 5 within five (5) working days.

 

5 / 16

 

 

6. 股东的声明和保证

 

The Shareholders’ Representations and Warranties

 

各股东特此向外商独资企业陈述和保证:

 

Each Shareholder hereby represents and warrants to the WFOE that:

 

6.1 各股东是质押股权的唯一合法所有人。

 

The Shareholder is the sole legal owner of the Pledged Equity Interest.

 

6.2 除本协议项下质押以外,各股东没有在质押股权上设置任何担保权益或其他权利负担。

 

Except for the Pledge, the Shareholder has not placed any security interest or other encumbrance on the Pledged Equity Interest.

 

6.3 各股东和众巢医学已经取得第三方和政府部门的同意及批准(若需)以签署,交付和履行本协议。

 

The Shareholder and Zhongchao have obtained any and all approvals and consents from applicable government authorities and third parties (if required) for the execution, delivery and performance of this Agreement.

 

6.4 本协议的签署、交付和履行均不会:(1)导致违反任何有关的中国法律;(2)与众巢医学章程或其他组织文件相抵触;(3)导致违反其是一方或对其有约束力的任何合同或文件,或构成其是一方或对其有约束力的任何合同或文件项下的违约;(4)导致违反有关向任何一方颁发的任何许可或批准的授予和(或)继续有效的任何条件;或(5)导致向任何一方颁发的任何许可或批准中止或被撤销或附加条件。

 

The execution, delivery and performance of this Agreement will not: (i) violate any relevant PRC laws; (ii) conflict with Zhongchao’s articles of association or other constitutional documents; (iii) result in any breach of or constitute any default under any contract or instrument to which it is a party or by which it is otherwise bound; (iv) result in any violation of any condition for the grant and/or maintenance of any permit or approval granted to any Party; or (v) cause any permit or approval granted to any Party to be suspended, cancelled or attached with additional conditions.

 

7. 股东的承诺和进一步保证

 

The Shareholders’ Covenants and Further Assurance

 

7.1 股东在此向外商独资企业承诺,在本协议有效期内,股东:

 

The Shareholders hereby jointly and severally covenant to the WFOE, that during the term of this Agreement, the Shareholders shall:

 

7.1.1 如未获外商独资企业事先书面同意,不得转让质押股权,或在质押股权上设置或允许设置任何担保权益或其他权利负担,或以其他任何方式处置质押股权,但为履行独家购股权协议的除外;

 

without the WFOE’s prior written consent, not transfer the Pledged Equity Interest, establish or permit the existence of any security interest or other encumbrance on the Pledged Equity Interest, or dispose of the Pledged Equity Interest by any other means, except by the performance of the Exclusive Option Agreement;

 

6 / 16

 

 

7.1.2 遵守适用于质押的所有相关法律法规的规定,在收到相关监管机构就质押发出或起草的任何通知、命令或建议的五(5)个工作日内,向外商独资企业提交该通知、命令或建议,并遵守前述通知、命令或建议,或应外商独资企业合理要求或获外商独资企业同意后,就上述事宜主张权利或提起申诉;

 

comply with the provisions of all laws and regulations applicable to the Pledge, and within five (5) working days of receipt of any notice, order or recommendation issued or prepared by relevant competent authorities regarding the Pledge, shall present the aforementioned notice, order or recommendation to the WFOE, and shall comply with the aforementioned notice, order or recommendation or submit claims and appeals with respect to the aforementioned matters upon the WFOE’s reasonable request or upon consent of the WFOE;

 

7.1.3 知晓或收到相关事件或通知且该事件或通知可能会对外商独资企业就质押股权享有的权利或股东在本协议项下的其他义务产生影响,股东应立即告知外商独资企业。

 

promptly notify the WFOE of any event or notice received by the Shareholders that may have an impact on the WFOE’s rights to the Pledged Equity Interest or any portion thereof or other obligations of the Shareholders arising out of this Agreement.

 

7.2 股东同意,外商独资企业依据本协议获得的与质押相关的权利,不得由众巢医学、股东、股东的承继人或代表、或任何其他人(以下合称相关人员)通过任何法律程序中断或妨害。

 

The Shareholders agree that the rights acquired by the WFOE in accordance with this Agreement with respect to the Pledge shall not be interrupted or harmed by Zhongchao, the Shareholders or any heirs or representatives of the Shareholders or any other persons (collectively, the “Relevant Persons”) through any legal proceedings.

 

7.2.1 未经外商独资企业事先书面同意,相关人员不会通过任何形式补充、变更或修改众巢医学的公司章程、内部细则或其他组织文件,不会增减众巢医学的注册资本,也不会通过其他方式变更众巢医学的注册资本结构;

 

Without the prior written consent of the WFOE, the Relevant Persons shall not in any manner supplement, change or amend the articles of association, bylaws or other documents of Zhongchao, increase or decrease its registered capital, or change the structure of its registered capital in other manners;

 

7 / 16

 

 

7.2.2 未经外商独资企业事先书面同意,相关人员不会在本协议签署后通过任何方式出售、转让、抵押或处置众巢医学的任何资产或众巢医学业务或收入中的法定或受益权益,也不会允许设置任何相关的担保权益或其他权利负担;或

 

Without the prior written consent of the WFOE, the Relevant Persons shall not at any time following the date hereof, sell, transfer, mortgage or dispose of in any manner any assets of Zhongchao or legal or beneficial interest in the business or revenues of Zhongchao, or allow the encumbrance thereon of any security interest or other encumbrance; or

 

7.2.3 未经外商独资企业事先书面同意,相关人员应确保众巢医学不会通过任何方式向股东分配股息、作出财产分配、减少资本、启动清算程序或以其他任何形式作出分配。任何分配(包括但不限于分配的资产或清算中的剩余财产)均应视为质押的一部分。

 

Without the prior written consent of the WFOE, the Relevant Persons shall ensure that Zhongchao shall not in any manner distribute dividends to its shareholder(s), make asset distributions or reduce its capital or initiate liquidation procedures or make any other distributions. Any distributions, including without limitation, the distributed assets or the residual assets in liquidation shall be deemed as part of the Pledge.

 

7.3 为保护或完善本协议对主协议款项支付所设的担保权益,股东特此承诺将诚信签署、并促使与质押有关的其他方签署外商独资企业要求的全部证明、协议、契约和/或承诺。全体股东还承诺采取、并促使与质押有关的其他方采取外商独资企业为行使本协议赋予其的权利和权力而要求的行动,并与外商独资企业或其指定人签署与质押股权所有权相关的所有文件。全体股东承诺在合理时间内向外商独资企业提供外商独资企业要求的与质押相关的全部通知、命令和决定。

 

To protect or perfect the security interest granted by this Agreement for payments under the Principal Agreements, the Shareholders hereby undertake to execute in good faith and to cause other parties who have interests in the Pledge to execute all certificates, agreements, deeds and/or covenants required by the WFOE. The Shareholders also undertake to perform and to cause other parties who have interests in the Pledge to perform actions required by the WFOE, to facilitate the exercise by the WFOE of its rights and authority granted thereto by this Agreement, and to execute all relevant documents regarding ownership of the Pledged Equity Interest with the WFOE or its designee(s). The Shareholders undertake to provide the WFOE within a reasonable time with all notices, orders and decisions regarding the Pledge that are required by the WFOE.

 

7.4 股东特此承诺遵守并履行本协议下的所有保证、承诺、约定、陈述和条件。如果未能履行或仅部分履行上述保证、承诺、约定、陈述和条件,股东应向外商独资企业赔偿因此导致的全部损失。

 

The Shareholders hereby undertake to comply with and perform all guarantees, promises, agreements, representations and conditions under this Agreement. In the event of failure to perform all or part of such guarantees, promises, agreements, representations and conditions, the Shareholders shall indemnify the WFOE for all losses resulting therefrom.

 

8 / 16

 

 

8. 行使质权

 

Exercise of Pledge

 

8.1 以下事件将构成本协议下的违约事件(“违约事件”)(违约事件将被视为“持续”,除非已被补救或豁免):

 

Each of the following shall constitute an event of default (“Event of Default”) hereunder (and an Event of Default is “continuing” if it has not been remedied or waived):

 

(i) 股东、众巢医学在本协议或任何主协议下作出的任何陈述、保证或声明在任何方面不真实、不完整或不准确;或,股东、众巢医学违反或未能履行本协议或任何主协议下的任何义务、或未能遵守本协议或任何主协议下的任何承诺;或

 

any statement, warranty or representation made by the Shareholders or Zhongchao under this Agreement or any of the Principal Agreements are not true, complete or accurate in any aspect; or the Shareholders or Zhongchao breach or fail to fulfill any obligation or abide by any covenants and undertakings under this Agreement or any Principal Agreements; or

 

(ii) 股东、众巢医学在本协议或任何主协议下的一项或多项义务被视为不合法或者无效;

 

any or more of the obligations of the Shareholders or Zhongchao under this Agreement or any of the Principal Agreements are deemed as unlawful or void.

 

8.2 一旦发生违约事件以及在违约事件持续的过程中,外商独资企业有权要求股东立即支付众巢医学在服务协议项下之所有未偿款项、偿还任何贷款及支付所有其他应付款项,及外商独资企业有权根据相关有效中国法律行使被担保方的所有权利(包括《中华人民共和国担保法》和《中华人民共和国物权法》中的规定),这些权利包括但不限于:

 

Upon the occurrence and during the continuance of an Event of Default, the WFOE shall have the right to require the Shareholders to immediately pay any amount payable by Zhongchao under the Service Agreement, repay any loans and pay any other due payments, and the WFOE shall have the right to exercise all such rights as a secured party under any applicable PRC law, including the Guarantee Law of the People's Republic of China and the Property Law of the People’s Republic of China, as in effect from time to time, including without limitations:

 

(i) 通过向质押人提前三(3)天发出书面通知,在一个或多个公开或私有交易场合出售部分或全部质押股权,且该等出售可以是以现金、信用交易或未来交付的方式进行;或

 

to sell all or any part of the Pledged Equity Interest at one or more public or private sales upon three (3) days’ written notice to the pledgor, and any such sale or sales may be made for cash, upon credit, or for future delivery; or

 

(ii) 以通过参考质押物的市场价格所确定的货币价值或各方同意的其他价格,与股东签署协议购买质押股权。

 

to execute an agreement with the Shareholders to acquire the Pledged Equity Interest based on its monetary value which shall be determined by referencing the market price of the pledged property or another price as agreed between parties.

 

9 / 16

 

 

8.3 如外商独资企业要求,股东和众巢医学应采取所有合法和适当的行动,保证外商独资企业行使其质押权利。就前述而言,股东和众巢医学应按外商独资企业合理要求,签署所有文件和材料及采取所有措施和行动。

 

The Shareholders and Zhongchao, at the request of the WFOE, shall take all lawful and appropriate actions to secure the WFOE’s exercise of the Pledge right. For the purpose of the foregoing, the Shareholders and Zhongchao shall sign all the documents and materials and carry out all measures and take all actions reasonably required by the WFOE.

 

9. 转让

 

Assignment

 

9.1 未获外商独资企业事先书面同意,众巢医学和股东不得向任何第三方转让其各自在本协议项下的任何权利和义务。

 

Zhongchao and the Shareholders shall not assign any of their respective rights or obligations under this Agreement to any third party without the prior written consent of the WFOE.

 

9.2 众巢医学和股东特此同意,外商独资企业可以其完全自主判断自行转让其在本协议项下的权利和义务,且仅需向众巢医学和股东发出书面通知。

 

Zhongchao and the Shareholders hereby agree that the WFOE may assign its rights and obligations under this Agreement as the WFOE may decide, at its sole discretion, and such transfer shall only be subject to a written notice sent to Zhongchao and the Shareholders.

 

9.3 本协议的条款和条件应为当事方各自的继承人和经许可的受让人之利益而生效,并应约束当事方各自的继承人和受让人。除非本协议明示规定,本协议的任何规定(明示和默示的)均不意图赋予除本协议当事方或其各自继承人和受让人之外的任何他方本协议项下或源于本协议的任何权利、救济、义务、或责任。

 

The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the Parties. Save as expressly provided in this Agreement, nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement.

 

10. 完整协议和协议修改

 

Entire Agreement and Amendment to Agreement

 

10.1 本协议及本协议中明确提到或包含的全部约定和/或文件,构成关于本协议标的事项的完整协议,取代各方先前就本协议标的事项达成的所有口头约定、合同、谅解和交流。

 

This Agreement and all agreements and/or documents mentioned or included explicitly by this Agreement constitute the complete agreement with respect to the subject matter of this Agreement and shall supersede any and all prior oral agreements, contracts, understandings and communications made by the Parties with respect to the subject matter of this Agreement.

 

10 / 16

 

 

10.2 对本协议的任何修改应以书面方式作出,并仅在本协议各方签字后生效。经各方正式签 署的修改协议或补充协议构成本协议的组成部分,与本协议具有同等法律效力。

 

Any modification of this Agreement shall be made in a written form and shall only become effective upon execution by all Parties of this Agreement. Modifications and supplements to this Agreement duly executed by the Parties shall be parts of this Agreements and shall have the same legal effect as this Agreement.

 

11. 管辖法律

 

Governing Law

 

本协议受中国法律管辖且据其进行解释。

 

This Agreement shall be construed in accordance with and governed by the laws of China.

 

12. 争议解决

 

Dispute Resolution

 

12.1 因本协议产生或与本协议相关的任何争议或主张应由各方通过友好协商的方式解决。如果各方未能解决争议,应将争议提交到上海国际经济贸易仲裁委员会(“仲裁委),由仲裁委按照申请仲裁时有效的仲裁委仲裁规则经由仲裁解决。仲裁地为上海,仲裁语言为中文。只用一名仲裁员仲裁,该仲裁员由仲裁委指定。仲裁裁决具终局性且对各方都有约束力。

 

Any dispute or claim arising out of or in connection with or relating to this Agreement shall be resolved by the Parties in good faith through negotiations. In case no resolution can be reached by the Parties, such dispute shall be submitted to the Shanghai International Economic and Trade Arbitration Commission (the “Arbitration Commission”) for arbitration in accordance with its rules of arbitration in effect at the time of applying for such arbitration and the place of arbitration shall be in Shanghai, and the language of arbitration shall be Chinese. The arbitration tribunal shall be composed of only one arbitrator, which shall be appointed by the arbitration commission. The arbitral award shall be final and binding upon all Parties.

 

12.2 在争议解决和仲裁程序进行过程中,除了本协议正在仲裁的事宜以外,各方应在实际可行的前提下继续履行本协议。每一方应自行承担为解决任何争议而发生的费用,但仲裁费应由各方平均分担。

 

Throughout any dispute resolution and arbitration proceedings, the Parties shall continue to perform this Agreement, to the extent practical, with the exception of the matter that is under arbitration. Each Party shall be responsible for its own expenses in connection with resolving any Dispute, but the arbitration fees shall be shared equally.

 

13. 生效日和期限

 

Effective Date and Term

 

13.1 本协议应于文首所载日期签署之日起生效。

 

This Agreement shall be signed and shall take effect as of the date set forth above.

 

13.2 本协议在质押存续期间持续有效。

 

This Agreement shall remain effective as long as the Pledge exists.

 

11 / 16

 

 

14. 通知

 

Notices

 

任何一方按本协议规定发出的通知或其他通信应以英文或中文语书写,并可以专人递送、挂号邮寄、邮资预付邮寄、或受承认的专递服务或发送传真的形式发送到有关各方不时指定的收件地址。通知被视为实际到达的日期,应按如下方式确定:(a)专人递送的通知,专人递送当日即视为已实际送达;(b)用信函发出的通知,则在邮资付讫的航空挂号信寄出日(依邮戳为准)后的第十(10)天,即视为已实际送达,或在送交专递服务公司后的第四(4)天,即视为已实际送达;以及(c)用传真发送的通知,在有关文件的传送确认单上所显示的接收时间,即视为已实际送达。

 

Notices or other communications required to be given by any party pursuant to this Agreement shall be written in English and Chinese and delivered personally or sent by registered mail or postage prepaid mail or by a recognized courier service or by facsimile transmission to the address of each relevant party as specified by such party from time to time. The date when a notice is deemed to be duly served shall be determined as follows: (a) a notice delivered personally is deemed duly served upon delivery; (b) a notice sent by mail is deemed duly served on the tenth (10th) day after the date when the postage prepaid registered airmail is posted (as evidenced by the postmark), or on the fourth (4th) day after the date when the notice is delivered to an internationally-recognized courier service agency; and (c) a notice sent by facsimile transmission is deemed duly served upon receipt as evidenced by the time shown in the transmission confirmation for the relevant documents.

 

15. 可分割性

 

Severability

 

如果本协议项下的任何条款因与有关法律不一致而无效或不可执行,则该条款仅在有关法律的管辖范围之内被视为无效或不可执行,并且本协议其他条款的有效性,合法性和可强制执行性不受其影响。

 

If any provision of this Agreement is judged to be invalid or unenforceable because it is inconsistent with applicable laws, such invalidity or unenforceability shall be only with respect to such laws, and the validity, legality and enforceability of the other provisions hereof shall not be affected.

 

16. 文本

 

Counterparts

 

本协议由协议各方签署四(4)份原件,各方各执一(1)份,所有原件具有同等法律效力。本协议可以一份或多份副本方式签署。

 

This Agreement shall be executed in four (4) originals by all Parties, with each Party holding one (1) original. All originals shall have the same legal effect. The Agreement may be executed in one or more counterparts.

 

17. 语言

 

Languages

 

本协议的英文文本和中文文本具有同等法律效力。若英文文本和中文文本有任何不一致的约定,应以中文文本的相关内容为准。

 

Both Chinese and English versions of this Agreement shall have equal validity. In case of any discrepancy between the English version and the Chinese version, the Chinese version shall prevail.

 

 

[后附签字页Signature Pages Follow]

 

12 / 16

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

 

北京众巢众行科技有限公司

 

Beijing Zhongchao Zhongxing Technology Co.,Ltd.

 

授权代表(Authorized Representative): /s/ Weiguang Yang

 

13 / 16

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

 

众巢医学科技(上海)有限公司

 

Zhongchao Medical Technology (Shanghai) Co., Ltd.

 

授权代表(Authorized Representative): /s/ Weiguang Yang.

 

14 / 16

 

  

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

 

杨伟光

 

Weiguang Yang

 

授权代表(Authorized Representative): /s/ Weiguang Yang

 

15 / 16

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

 

上海行众投资管理合伙企业(有限合伙)

 

Shanghai Xingzhong Investment Management LP, Ltd.

 

签字/Signature: /s/ Weiguang Yang.

 

 

16 / 16

 

 

Exhibit 10.2

  

委托协议及授权委托书

 

PROXY AGREEMENT AND POWER OF ATTORNEY

 

本委托协议及授权委托书(“本协议”)于2020年 9 10 日由以下各方于上海订立:

 

This Proxy Agreement and Power of Attorney(this “Agreement”)is entered into in Shanghai as of September 10th , 2020 by and among the following parties:

 

(1) 北京众巢众行科技有限公司(“外商独资企业”),一家根据中华人民共和国(“中国”)法律在中国北京注册成立的外商独资企业;和

 

Beijing Zhongchao Zhongxing Technology Co.,Ltd. (the “WFOE”), a wholly foreign-owned enterprise registered in Beijing, the People's Republic of China (“China” or “PRC”), under the laws of China; and

 

(2) 众巢医学科技(上海)有限公司“众巢医学”),一家根据中国法律在中国上海注册成立的内资公司;和

 

Zhongchao Medical Technology (Shanghai) Co., Ltd. (“Zhongchao”), a domestic company registered in Shanghai, China, under the laws of China; and

 

3) 在附件1列明的每一方(以下这样的个人单独称为 “一位股东”,合称为“股东”)

 

Each of the parties listed under Schedule 1 (each, a “Shareholder” and collectively, the “Shareholders”)

 

(以上外商独资企业、众巢医学和每一位股东单独称为“一方”,合称为“各方”) 。

 

(Each of the WFOE, Zhongchao and each of the Shareholders, a “Party”, and collectively the “Parties”).

  

序言

 

RECITALS

 

(A) 鉴于,股东持有众巢医学100%的股权;

 

WHEREAS, the Shareholders hold 100% equity interest in Zhongchao.

 

B) 鉴于,外商独资企业、众巢医学及股东间签署了《独家服务总协议》、《业务合作协议》、《独家购股权协议》和《股权质押协议》;这一系列协议为众巢医学的正常经营提供服务,同时保证外商独资企业对众巢医学具有全面、持续、有效的控制;

 

WHEREAS, the WFOE, Zhongchao and Shareholders have entered into Master Exclusive Service Agreement, Business Cooperation Agreement, Exclusive Option Agreement and Equity Interest Pledge Agreement; these contractual arrangements provide Zhongchao with services necessary for its business operation and also ensure that the WFOE has comprehensive, continuous and effective control over Zhongchao ;

 

1 / 13

 

 

(C) 鉴于,作为为众巢医学的正常经营持续提供服务的对价,外商独资企业要求股东授权外商独资企业(及其继任者,包括取代外商独资企业的清算人,如涉及)为股东的受托人(“受托人”),由受托人全权代替股东行使其就所持众巢医学之股权享有的任何及所有权利,且股东同意对外商独资企业给予授权委托。

 

WHEREAS, as the consideration for the WFOE and its affiliates to provide Zhongchao with services necessary for its business operation, the WFOE has requested the Shareholders to appoint the WFOE (as well as its successors, including a liquidator, if any, replacing the WFOE) as its attorney-in-fact (“Attorney-in-Fact”), with full power of substitution, to exercise any and all of the rights in respect of the Shareholders’ equity interest in Zhongchao and the Shareholders have agreed to make such appointment.

 

因此,基于本协议包含的前提、陈述、保证、承诺和约定,本协议各方约定如下并接受其法律效力:

 

NOW, THEREFORE, in consideration of the premises and the representations, warranties, covenants and agreements herein contained, and intending to be legally bound hereby, the Parties hereby agree as follows:

  

协议

 

AGREEMENT

 

Section 1 第1条

 

每一位股东在此不可撤销地选定、委托及任用外商独资企业(及其继任者,包括取代外商独资企业的清算人,如涉及)为其受托人代表该股东行使相关法律法规及众巢医学的公司章程规定的就该股东所持众巢医学之股权而享有的任何及所有权利(包括但不限于以下所列权利)(合称“股东权利”):

 

Each Shareholder hereby irrevocably nominates, appoints and constitutes the WFOE (as well as its successors, including a liquidator, if any, replacing the WFOE) as its Attorney-in-Fact to exercise on such Shareholder’s behalf any and all rights that such Shareholder has in respect of such Shareholder’s equity interest in Zhongchao conferred by relevant laws and regulations and the articles of association of Zhongchao, including without limitation, the following rights (collectively, “Shareholder Rights”):

 

(a) 召集及参加众巢医学股东会,接收股东会通知及相关资料(为本协议之目的,除另有明确约定,“股东会”包含“股东大会”之意义);

 

To call and attend shareholders’ meetings of Zhongchao , and receive notices and materials with respect to the shareholders meeting (as for the purpose of this Agreement, unless otherwise stipulated herein, “shareholdersmeetings” includes the meaning of “the general meeting” );

 

2 / 13

 

 

(b) 以股东的名义、代表股东签署及交付任何书面决议和会议记录;

 

to execute and deliver any and all written resolutions and meeting minutes in the name and on behalf of such Shareholder;

 

(c) 亲自或委派代表就众巢医学的股东会讨论的任何事项(包括但不限于出售、转让、抵押、质押或处分众巢医学的任何或全部资产)进行投票表决;

 

to vote by itself or by proxy on any matters discussed on shareholders’ meetings of Zhongchao , including without limitation, the sale, transfer, mortgage, pledge or disposal of any or all of the assets of Zhongchao;

 

(d) 出售、转让、质押或处分在众巢医学的任何或全部股权;

 

to sell, transfer, pledge or dispose of any or all of the equity interest in Zhongchao;

 

(e) 如有必要,提名或任免众巢医学的董事、监事和高级管理人员;

 

to nominate, appoint or remove the directors, supervisors and senior management of Zhongchao when necessary;

 

(f) 监督众巢医学的经营绩效;

 

to oversee the economic performance of Zhongchao;

 

(g) 在任何时候查阅众巢医学的财务信息;

 

to have full access to the financial information of Zhongchao at any time;

 

(h) 当众巢医学的董事或高级管理人员的行为损害众巢医学或其股东利益时,对该等董事或高级管理人员提起股东诉讼或其它法律行动;

 

to file any shareholder lawsuits or take other legal actions against Zhongchao’s directors or senior management members when such directors or members are acting to the detriment of the interest of Zhongchao or its shareholder(s);

 

(i) 批准年度预算或宣布分红;

 

to approve annual budgets or declare dividends;

 

(j) 管理和处置众巢医学的资产;

 

to manage and dispose of the assets of Zhongchao;

 

(k) 对众巢医学的财务、会计和日常经营有完全的控制权和管理权(包括但不限于签署合同、支付政府税项);

 

to have the full rights to control and manage Zhongchao’s finance, accounting and daily operation (including but not limited to signing and execution of contracts and payment of government taxes and duties);

 

3 / 13

 

 

(l) 批准向政府主管机关递交任何审批登记文件;以及

 

to approve the filing of any documents with the relevant governmental authorities or regulatory bodies; and

 

(m) 众巢医学的公司章程或及相关法律法规赋予股东的任何其他权利。

 

any other rights conferred by the articles of association of Zhongchao and/or the relevant laws and regulations on the shareholders.

 

股东进一步同意并承诺,未经受托人事先书面同意,股东不得行使任何股东权利。

 

Each Shareholder further agrees and undertakes that without the Attorney-in-Fact’s prior written consent, it shall not exercise any of the Shareholder Rights.

 

Section 2 第2条

 

受托人有权完全自主决定委任一名或多名替换人选,行使受托人在本协议项下的任何或全部权利,受托人亦有权自主决定撤销对该等替换人选的委任。

 

The Attorney-in-Fact has the right to appoint, at its sole discretion, a substitute or substitutes to perform any or all of its rights of the Attorney-in-Fact under this Agreement, and to revoke the appointment of such substitute or substitutes.

 

Section 3 第3条

 

众巢医学确认、承认并同意受托人代表股东行使任何及全部的股东权利。众巢医学进一步确认并承认:(i)受托人已进行或将进行的任何行为,已作出或将作出的任何决定,或已签署或将签署的任何文书或其他文件视同股东本人进行的行为、股东本人作出的决定或股东本人签署的文件,具有同等法律效力;及(ii)对于股东违反本协议规定采取或实施的任何行为,众巢医学将不认可,也不会对此予以配合或协助。

 

Zhongchao confirms, acknowledges and agrees to the appointment of the Attorney-in-Fact to exercise any and all of the Shareholder Rights. Zhongchao further confirms and acknowledges that (i) any and all acts done or to be done, decisions made or to be made, and instruments or other documents executed or to be executed by the Attorney-in-Fact, shall therefore be as valid and effectual as though done, made or executed by the Shareholders, and (ii) Zhongchao will not recognize and facilitate any and all activities of the Shareholders which are in violation of or inconsistent with this Agreement.

 

4 / 13

 

 

Section 4 第 4 条

 

(a) 每一位股东均在此同意,如果股东在众巢医学中所持股权有所增加,无论是否通过认购众巢医学的新增注册资本的方式,股东对于所增持股权所享有的任何股东权利均受本协议制约,受托人均有权代表股东对任何增持股权行使本协议第1条规定的股东权利;同样,如果任何人取得众巢医学股权,无论是通过自愿转让、依法转让、强制拍卖还是任何其他方式,该受让人所取得所有众巢医学之股权仍旧受本协议制约,受托人有权继续对该等股权行使本协议第1条规定的股东权利。

 

(a) Each Shareholder hereby acknowledges that, if the Shareholder increases its equity interest in Zhongchao, whether by subscribing for additional registered capital thereof or otherwise, any Shareholder Rights in connection with such additional equity interest acquired by the Shareholder shall be automatically subject to this Agreement and the Attorney-in-Fact shall have the right to exercise the Shareholder Rights with respect to such additional equity interest on behalf of the Shareholder as described in Section 1 hereunder; if the Shareholder’s equity interest in Zhongchao is transferred to any other party, whether by voluntary transfer, judicial sale, foreclosure sale, or otherwise, any such equity interest in Zhongchao so transferred remains subject to this Agreement and the Attorney-in-Fact shall continue to have the right to exercise the Shareholder Rights with respect to such equity interest in Zhongchao so transferred as described in Section 1 hereunder.

 

(b) 为避免任何疑问,若股东需要根据其与外商独资企业或其关联方签订的《独家购股权协议》、《股权质押协议》(包括不时修改后的版本)向外商独资企业或其关联方转让股权,受托人有权代表股东签署股权转让协议及其他相关协议,履行股东于《独家购股权协议》及《股权质押协议》项下的所有义务。若外商独资企业提出要求,股东应签署任何文件、加盖公章和/或印章,并采取任何其他必要行动以完成前述股权转让。

 

(b) Furthermore, for the avoidance of any doubt, if any equity interest transfer is contemplated under any exclusive option agreement and equity interest pledge agreement(s) that such Shareholder enters into for the benefits of the WFOE or its affiliate (as may be amended from time to time), the Attorney-in-Fact shall, on behalf of the Shareholder, have the right to sign the equity interest transfer agreement and other relevant agreements and to perform all shareholder obligations under the exclusive option agreement and the equity interest pledge agreement(s). If required by the WFOE, the Shareholder shall sign any documents and fix the chops and/or seals thereon and the Shareholder shall take any other actions as necessary for purposes of consummation of the aforesaid equity interest transfer.

 

Section 5 第5条

 

股东进一步同意并向外商独资企业承诺,假如股东由于其在众巢医学的股权利益收到任何股息、利息、任何其他形式的资本分派、清算后剩余财产、或因股权转让产生的收入或对价,股东将会在法律允许的范围内,将所有这些股息、利息、资本分派、资产、收入或对价给予外商独资企业或其指定的实体而不要求任何补偿,并承担因此产生的任何税费。

 

Each Shareholder further covenants with and undertakes to the WFOE that, if the Shareholder receives any dividends, interest, any other forms of capital distributions, residual assets upon liquidation, or proceeds or consideration from the transfer of equity interest as a result of, or in connection with, such Shareholder’s equity interest in Zhongchao , the Shareholder shall, to the extent permitted by applicable laws, remit all such dividends, interest, capital distributions, assets, proceeds or consideration to the WFOE or the entity designated by the WFOE without any compensation, and shall bear any and all taxes and fees with respect thereto.

 

5 / 13

 

 

Section 6 第6条

 

每一位股东特此授权受托人依其完全自主判断行使股东权利,并且无需获得股东的任何口头或书面指示。股东承诺批准并认可受托人或其委任的任何替换人士或代理人根据本协议作出的或促使作出的任何合法行为。

 

Each Shareholder hereby authorizes the Attorney-in-Fact to exercise the Shareholder Rights according to its own judgment without any oral or written instruction from the Shareholder. Each Shareholder undertakes to ratify any acts which the Attorney-in-Fact or any substitutes or agents appointed by the Attorney-in-Fact may lawfully do or cause to be done pursuant to this Agreement.

 

Section 7 第7条

 

本协议经各方授权代表正式签署,自本协议标明的签署之日起生效,于众巢医学存续期间持续有效。未经外商独资企业事先书面同意,股东无权终止本协议或撤销对受托人的委任。本协议对各方的权利继续人、受让人具有法律约束力。

 

This Agreement shall become effective as of the date hereof when it is duly executed by the Parties’ authorized representatives and shall remain effective as long as Zhongchao exists. The Shareholders shall not have the right to terminate this Agreement or revoke the appointment of the Attorney-in-Fact without the prior written consent of the WFOE. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their successors and assigns.

 

Section 8 第8条

 

本协议构成各方之间就本协议标的事项所达成的完整协议。

 

This Agreement constitutes the entire agreement between the Parties with respect to the subject matter hereof.

 

Section 9 第9条

 

本协议根据中国法律解释并受其管辖。

 

This Agreement shall be construed in accordance with and governed by the laws of China.

 

Section 10 第10条

 

因本协议产生或与本协议相关的任何争议或主张应由各方通过友好协商的方式解决。如果外商独资企业和众巢医学及股东各方未能解决争议,应将争议提交到上海国际经济贸易仲裁委员会(“仲裁委”),由仲裁委按照申请仲裁时有效的仲裁委仲裁规则经由仲裁解决。仲裁地为上海,仲裁语言为中文。只用一名仲裁员仲裁,该仲裁委员由仲裁委指定。仲裁裁决具终局性且对各方都有约束力。

 

Any dispute or claim arising out of or in connection with or relating to this Agreement shall be resolved by the Parties in good faith through negotiations. In case no resolution can be reached by the Parties, such dispute shall be submitted to the Shanghai International Economic and Trade Arbitration Commission (the “Arbitration Commission”) for arbitration in accordance with its rules of arbitration in effect at the time of applying for such arbitration and the place of arbitration shall be in Shanghai, and the language of arbitration shall be Chinese. The arbitration tribunal shall be composed of only one arbitrator, which shall be appointed by the arbitration commission. The arbitral award shall be final and binding upon all Parties.

 

6 / 13

 

 

在争议解决和仲裁程序进行过程中,除了本协议正在仲裁的事宜以外,各方应在实际可行的前提下继续履行本协议。每一方应自行承担为解决任何争议而发生的费用,但仲裁费应由各方平均分担。

 

Throughout any dispute resolution and arbitration proceedings, the Parties shall continue to perform this Agreement, to the extent practical, with the exception of the matter that is under arbitration. Each Party shall be responsible for its own expenses in connection with resolving any Dispute, but the arbitration fees shall be shared equally.

 

Section 11 第11条

 

如一方存在以下情形,则该方应就该等情形给另一方造成的损失、损害、责任、被索赔损失等(包括合理的律师费,“损失”)依照另一方的要求立即予以赔偿,以使另一方免受损失:(1)该一方在本协议中所作的任何陈述或保证不真实、不准确或不完整,或者(2)该一方违反了其在本协议中所作的任何陈述或保证,或者(3)该一方违反了其在本协议中任何约定或承诺;但如果另一方遭受的损失系由于该另一方或该另一方的董事、管理人员、雇员或者代理人自身的故意行为不当、违反法律、违约行为、重大过失造成的,则违约方无需对另一方予以赔偿。各方同意本协议终止或失效时,本条仍然有效。

 

Either Party shall forthwith on demand indemnify and hold harmless the other Party against any claim, loss, liability or damage (including reasonable legal fees, “Loss”) which the other Party shall suffer due to any of the following circumstances: (i) any of the representations or warranties herein made by such Party is untrue, inaccurate or incomplete, or (ii) such Party breaches any of its representations or warranties herein, or (iii) such Party breaches any covenant or undertaking herein; provided that neither Party shall be liable to indemnify the other Party for any Loss to the extent that such Loss arises from the willful misconduct, breach of applicable law, regulation or contractual obligation or from the material negligence of the other Party or its directors, officers, employees, or agents. The Parties agree that this clause shall survive the termination or expiration of this Agreement.

 

Section 12 第12条

 

未经外商独资企业事先书面同意,众巢医学或任一位股东不得将其在本协议项下的权利和义务转让给任何第三方。

 

Zhongchao or either Shareholder shall not assign any of its rights or obligations under this Agreement to any third party without the prior written consent of the WFOE.

 

7 / 13

 

 

众巢医学和各股东在此同意,外商独资企业可转让其在本协议项下的权利和义务。外商独资企业仅需就该转让向众巢医学及各股东发出书面通知。

 

Zhongchao and the Shareholders hereby agree that the WFOE may assign its rights and obligations under this Agreement, only subject to a written notice to Zhongchao and the Shareholders.

 

本协议的条款和条件应为当事方各自的继承人和经许可的受让人之利益而生效,并应约束当事方各自的继承人和受让人。除非本协议明示规定,本协议的任何规定(明示和默示的)均不意图赋予除本协议当事方或其各自继承人和受让人之外的任何他方本协议项下或源于本协议的任何权利、救济、义务、或责任。

 

The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the Parties. Save as expressly provided in this Agreement, nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement.

 

Section 13 第13条

 

本协议可以一份或多份副本形式签署。全部原件具有相同的法律效力。

 

This Agreement may be executed in one or more counterparts. All originals shall have the same legal effect.

 

Section 14 第14条

 

本协议中英文版本具有相同的效力。若中文和英文有不一致,以中文文本为准。

 

Both Chinese and English versions of this Agreement shall have equal validity. In case of any discrepancy between the English version and the Chinese version, the Chinese version shall prevail.

  

[后附签字页Signature Pages Follow]

 

8 / 13

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

 

北京众巢众行科技有限公司

 

Beijing Zhongchao Zhongxing Technology Co.,Ltd.

 

授权代表(Authorized Representative):/s/ Weiguang Yang

 

9 / 13

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

  

众巢医学科技(上海)有限公司

 

Zhongchao Medical Technology (Shanghai) Co., Ltd.

 

授权代表(Authorized Representative): /s/ Weiguang Yang.

 

10 / 13

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

 

杨伟光

 

Weiguang Yang

 

签字/Signature: /s/ Weiguang Yang.

 

11 / 13

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

 

上海行众投资管理合伙企业(有限合伙)

 

Shanghai Xingzhong Investment Management LP, Ltd.

 

授权代表(Authorized Representative):/s/ Weiguang Yang.

  

12 / 13

 

 

SCHEDULE 1

 

附件1

 

Shareholders

 

股东

 

序号
No.
  姓名
Name
  证件号码/统一信用代码
No.
1.   杨伟光
Weiguang Yang
  362227198206170314
2.   上海行众投资管理合伙企业(有限合伙)
Shanghai Xingzhong Investment Management LP, Ltd.
  913101143584694449

 

 

 

13 / 13

 

 

Exhibit 10.3

 

配偶同意函

 

SPOUSAL CONSENT

 

致: 北京众巢众行科技有限公司

众巢医学科技(上海)有限责任公司

杨伟光

上海行众投资管理合伙企业(有限合伙)

 

To: Beijing Zhongchao Zhongxing Technology Co. Ltd.

Zhongchao Medical Technology (Shanghai) Co., Ltd.

Weiguang Yang

Shanghai Xingzhong Investment Management LP, Ltd.

 

本人,       郑志华       ,为杨伟光的合法配偶。本人在此无条件并不可撤销地同意杨伟光于2020年  9  月  10  日签署《业务合作协议》《独家购股权协议》《股权质押协议》《委托协议及授权委托书》(合称“VIE协议”),并同意按照上述协议的规定处置杨伟光持有的、并登记在其名下的众巢医学科技(上海)有限责任公司(“可变利益实体”)股权。

 

I,       Zhihua  Zheng      , am the lawful spouse of Weiguang Yang. I hereby consent unconditionally and irrevocably that a certain percentage of the shares in Zhongchao Medical Technology (Shanghai) Co., Ltd. (“Variable Interest Entity”) that is held by and registered in the name of my spouse, Weiguang Yang, will be disposed of pursuant to the arrangements under the Variable Interest Entity agreements (including the Business Cooperation Agreement, the Exclusive Option Agreement, the Equity Interest Pledge Agreement and the Proxy Agreement and Power of Attorney, which were executed by my spouse at    September 10th  , 2020 (the “VIE Agreements”).

 

1 / 3

 

 

本人承诺不就杨伟光持有的可变利益实体的股权提出任何主张。本人进一步确认,杨伟光履行VIE协议以及进一步修改或终止VIE协议并不需要本人另行授权或同意。

 

I hereby undertake not to make any assertions in connection with the equity interests of Variable Interest Entity which are held by Weiguang Yang. I hereby further confirm that Weiguang Yang can perform the VIE Agreements and further amend or terminate the VIE Agreements absent authorization or consent from me.

 

本人承诺将签署一切必要的协议,并采取一切必要的行动,以确保(经不时修订的)VIE协议得到适当履行。

 

I hereby undertake to execute all necessary documents and take all necessary actions to ensure appropriate performance of the VIE Agreements (as amended from time to time).

 

本人同意并承诺,如本人由于任何原因获得杨伟光持有的可变利益实体的任何股权,则本人应受(经不时修订的)VIE协议和北京众巢众行科技有限公司(“外商独资企业”)和可变利益实体于2019年  8    14  日签订的(经不时修订的)独家服务总协议的约束,并遵守作为可变利益实体的股东在(经不时修订的)VIE协议下的义务,且为此目的,一旦外商独资企业提出要求,本人应签署格式和内容基本与(经不时修订的)VIE协议和(经不时修订的)独家服务总协议相同的一系列书面协议。

 

I hereby agree and undertake that if I obtain any equity interests of Variable Interest Entity which are held by Weiguang Yang for any reasons, I shall be bound by the VIE Agreements and the Master Exclusive Service Agreement entered into between the Beijing Zhongchao Zhongxing Technology Co. Ltd. (“WFOE”) and Variable Interest Entity as of August 14th , 2019 (as amended from time to time) and comply with the obligations thereunder as a shareholder of Variable Interest Entity. For this purpose, upon the WFOE’s request, I shall sign a series of written documents in substantially the same format and content as the VIE Agreements (as amended from time to time) and Master Exclusive Service Agreement (as amended from time to time).

 

2 / 3

 

 

本配偶同意函中英文版本具有相同的效力。若中文和英文有不一致,以中文文本为准。

 

Both Chinese and English versions of this Spousal Consent shall have equal validity. In case of any discrepancy between the English version and the Chinese version, the Chinese version shall prevail.

 

  姓名:
  郑志华
   
  Name:
  Zhihua Zheng
   
  日期:2020年 9 月 10 日
  Date: September 10, 2020

 

 

3 / 3

 

 

Exhibit 10.4

 

业务合作协议

 

BUSINESS COOPERATION AGREEMENT

 

本业务合作协议(“本协议”)由以下各方于2020年      9           10      日在上海订立:

 

This Business Cooperation Agreement(the “Agreement”)is entered into in Shanghai as of September 10th , 2020 by and among the following parties:

 

(1) 北京众巢众行科技有限公司(“外商独资企业”),一家根据中华人民共和国(“中国”)法律在中国北京注册成立的外商独资企业;和

 

Beijing Zhongchao Zhongxing Technology Co.,Ltd. (the “WFOE”), a wholly foreign-owned enterprise registered in Beijing, the People's Republic of China (“China” or “PRC”), under the laws of China; and

 

(2) 众巢医学科技(上海)有限公司(“众巢医学”),一家根据中国法律在中国上海注册成立的内资公司;和

 

Zhongchao Medical Technology (Shanghai) Co., Ltd. (“Zhongchao”), a domestic company registered in Shanghai, China, under the laws of China; and

 

(3) 在附件1列明的每一方(以下单独称为“一名股东”,合称为“股东”)

 

Each of the parties listed under Schedule 1 (each, a “Shareholder” and collectively, the “Shareholders”)

 

(以上外商独资企业、众巢医学和每一位股东单独称为“一方”,合称为“各方”) 。

 

(Each of the WFOE, Zhongchao and each of the Shareholders, a “Party”, and collectively the “Parties”).

 

序言

 

RECITALS

 

(1) 鉴于,外商独资企业在多种类型业务方面已经具备了相关专业能力和实践经验;

 

WHEREAS, the WFOE engages in the business of and has the relevant expertise and practical experience in various areas;

 

(2) 鉴于,众巢医学在中国从事医学领域内的技术开发和技术咨询等业务。

 

WHEREAS, Zhongchao engages in the business of technology development and technology consultation and related business in the field of medicine;

 

1 / 17

 

 

(3) 鉴于,外商独资企业与众巢医学在2019年8月14日签署了一份《独家服务总协议》(“服务协议”),根据该协议众巢医学应向外商独资企业支付服务费;及

 

WHEREAS, the WFOE has entered into a Master Exclusive Service Agreement (the “Service Agreement”) dated August 14, 2019 with Zhongchao, pursuant to which the WFOE is entitled to receive service fees from Zhongchao; and

 

(4) 鉴于,股东持有众巢医学100%的股权。

 

WHEREAS, the Shareholders hold 100% equity interest in Zhongchao.

 

有鉴于此,基于本协议中包含的各项前提、声明、保证、承诺和约定,各方愿意受其法律约束,并达成如下约定:

 

NOW, THEREFORE, in consideration of the premises and the representations, warranties, covenants and agreements herein contained, and intending to be legally bound hereby, the Parties hereby agree as follows:

 

协议

 

AGREEMENT

 

1. 不作为承诺

 

Negative Covenants

 

为确保众巢医学履行其与外商独资企业所签服务协议和/或其他协议项下的义务,股东和众巢医学连带作出同意并承诺,未获外商独资企业的书面同意,众巢医学不得进行、股东亦应促使众巢医学不得进行,任何会对其资产、义务、权利或经营产生重大影响的交易,包括但不限于:

 

To ensure that Zhongchao perform its obligations under the Service Agreement and/or other agreements executed with the WFOE, the Shareholders and Zhongchao jointly and severally, agree and covenant that, without obtaining the WFOE’s written consent, Zhongchao shall not, and the Shareholders shall cause Zhongchao not to, engage in any transaction which may materially affect its asset, obligation, right or operation, including but not limited to:

 

(a) 其各自正常业务范围未涵盖的活动,或从事与其过往经营不一致的业务活动;

 

Any activities not within its normal business scope, or operating its business in a way that is inconsistent with its past practice;

 

(b) 合并、整合、兼并、收购、和主要业务及资产的重组以及向任何企业或其他组织进行收购或投资,设立合营企业、合伙或其他类似经济组织;

 

Merger, reorganization, acquisition or restructuring of its principal business or assets, or acquisition of or investment in any other enterprise or entity, or formation of any joint venture, partnership or of other similar entity;

 

(c) 向第三方提供、从第三方借入任何贷款、信贷或承担任何债务,但正常经营过程中发生的除外;

 

Offering any loan to any third party, incurring any debt from any third party, or assuming any debt other than in the ordinary course of business;

 

2 / 17

 

 

(d) 雇佣、变更或辞退任何董事或高管人员,制订或实施任何形式的员工激励计划,确定或更改高管薪酬;

 

Engaging, changing or dismissing any director or any senior management officer, formulate or implement any staff motivation scheme, determining or changing the salary of senior management officers;

 

(e) 向第三方出售、或从第三方获得、抵押/质押、许可第三方使用或以其他方式处置任何有形或无形资产,但正常经营过程中发生的除外;

 

selling to or acquiring from any third party, mortgaging, licensing or disposing of in other ways tangible or intangible assets, other than in the ordinary course of business;

 

(f) 发生、继承、担保或承受任何债务(但不包括在正常业务过程中发生的债务)或使用其资产向第三方提供担保以或其他形式提供保证,或在其资产上设置任何权利负担;

 

incurring, inheriting, assuming or guaranteeing any debt that are not incurred during the ordinary course of business, using its assets to provide security or other forms of guarantees to any third party, or setting up any other encumbrances over its assets;

 

(g) 对其章程或其他组织性文件进行补充、变更或修改,增减其注册资本或通过其他方式变更其注册资本结构;

 

Making any supplement, amendment or alternation to its articles of association or other constitutional documents, increasing or decreasing of its registered capital or changing the structure of its registered capital in other manners;

 

(h) 以任何方式进行股息、股权权益或股东权益的分配,但在外商独资企业书面要求时,众巢医学应立即向股东分配全部或部分可分配利润,然后再由股东立即并无条件地将上述分配支付或转移至外商独资企业;

 

Making distribution of dividend or equity interest or shareholding interest in whatever ways, provided that upon the WFOE’s written request, Zhongchao shall immediately distribute part or all distributable profits to its shareholder(s) who shall in turn immediately and unconditionally pay or transfer to the WFOE any such distribution;

 

(i) 签署任何重大合同,但在正常业务过程中签署的除外(就本段而言,重大合同的标准由外商独资企业自行判断);

 

Executing any material contract, except the contracts executed in the ordinary course of business (for purpose of this subsection, the WFOE may define a material contract at its sole discretion);

 

(j) 通过任何方式出售、转让、抵押或处置其业务或收入中的法定或受益权益,或允许设置任何相关的担保权益或其他权利负担;

 

Selling, transferring, mortgaging or disposing of in any manner any legal or beneficial interest in its business or revenues, or allowing the encumbrance thereon of any security interest or any other encumbrance;

 

3 / 17

 

 

(k) 解散、清算和分配剩余财产;或

 

Dissolution, conducting liquidation and distributing the residual assets; or

 

(l) 促使其任何分支机构或子公司发生上述行为或签署任何可能导致上述行为发生 的合同、协议或其他法律文件。

 

Causing any of its branches or subsidiaries to engage in any of the foregoing or enter into any contract, agreement or other legal documents which may lead to or result in any of the foregoing.

 

2. 业务经营和人员安排

 

Business Operation and Personnel Arrangement

 

2.1 众巢医学同意并向外商独资企业承诺,众巢医学和股东将促使众巢医学:(1)接受外商独资企业就众巢医学的人员安排和调任、日常运营、股息分配和财务管理系统所提出的建议,且众巢医学将相应地严格遵守和履行;(2)谨慎、有效地经营众巢医学公司业务和处理公司事务,按照良好的财务和商业标准及实务维持众巢医学的存续;(3)在经营众巢医学全部业务的正常运营过程中,一直保持众巢医学的资产价值,不得采取任何可能影响众巢医学业务状况和资产价值的任何行为/不作为;(4)在外商独资企业提出要求时提供有关众巢医学业务经营和财务状况的相关资料;(5)如外商独资企业要求,为众巢医学的资产和业务从符合外商独资企业要求的保险公司处购买并持有保险,保险金额和险种应符合同类公司购买的金额和种类;(6)如发生或可能发生与众巢医学的资产、业务或收入相关的任何诉讼、仲裁或行政程序,立即通知外商独资企业;(7)为保持众巢医学对其全部资产的所有权,应签署全部必要或适当的文件,采取全部必要或适当的行为,提出全部必要或适当的控告,或针对全部索赔提出必要和适当的抗辩。

 

Zhongchao agrees and covenants to the WFOE that Zhongchao shall, and the Shareholders shall cause Zhongchao to, (i) accept suggestions raised by the WFOE over the employee engagement and replacement, daily operation, dividend distribution and financial management systems of Zhongchao, and Zhongchao shall strictly abide by and perform accordingly; (ii) maintain Zhongchao’s corporate existence in accordance with good financial and business standards and practices by prudently and effectively operating its business and handling its affairs; (iii) operate all of Zhongchao’s businesses during the ordinary course of business to maintain the asset value of Zhongchao and refrain from any action/omission that may adversely affect Zhongchao’s operating status and asset value; (iv) provide the WFOE with information on Zhongchao’s business operations and financial condition at WFOE’s request; (v) if requested by the WFOE, procure and maintain insurance in respect of Zhongchao’s assets and business from an insurance carrier acceptable to the WFOE, at an amount and type of coverage typical for companies that operate similar businesses; (vi) immediately notify the WFOE of the occurrence or possible occurrence of any litigation, arbitration or administrative proceedings relating to Zhongchao’s assets, business or revenue; and (vii) execute all necessary or appropriate documents, take all necessary or appropriate actions and file all necessary or appropriate complaints or raise necessary and appropriate defenses against all claims so as to maintain the ownership by Zhongchao of all of its assets.

 

4 / 17

 

 

2.2 股东应仅指派由外商独资企业指定的人员作为众巢医学的董事,具体程序按相关法律、法规和公司章程规定进行。众巢医学应促成外商独资企业指定的人员担任众巢医学的总经理、首席财务官和其他高级管理人员职务。

 

The Shareholders shall only appoint persons designated by the WFOE to be the directors of Zhongchao in accordance with the procedures required by laws, regulations and relevant articles of association. Zhongchao shall cause the persons designated by the WFOE to be the general manager, chief financial officer and other senior management members of Zhongchao.

 

2.3 若外商独资企业指定的上述董事或高级管理人员辞职,或应外商独资企业的要求被辞退,股东、众巢医学应根据外商独资企业的要求将该名人员从众巢医学辞退,且应指派外商独资企业指定的其他人选继任该职位。

 

If any of the above directors or senior management members designated by the WFOE resigns from the relevant position or is dismissed at the request of the WFOE, the Shareholders or Zhongchao, as the case may be, shall dismiss such person from Zhongchao upon the WFOE’s request, and shall appoint any other person designated by the WFOE to hold such position.

 

2.4 众巢医学及其股东在此连带向外商独资企业承诺并与其约定,在根据众巢医学相关的内部审批政策签署任何重大合同(“重大”之定义由外商独资企业予以确定)之前,众巢医学应获得外商独资企业的相应批准。

 

Zhongchao together with its Shareholders hereby jointly and severally covenant to and agree with the WFOE that Zhongchao shall seek appropriate approval from the WFOE prior to entering into any material contract (the definition of “material” shall be determined by the WFOE) in accordance with relevant internal approval policy of Zhongchao.

 

3. 其他安排

 

Other Arrangements

 

鉴于(1)外商独资企业及其关联方已通过服务协议与众巢医学建立了业务关系,且(2)众巢医学进行的日常业务活动,将对众巢医学向外商独资企业或其关联方支付服务费用的能力产生重大影响,股东同意,除非外商独资企业要求:

 

Given (i) that the business relationship between the WFOE (together with its affiliates) and Zhongchao has been established through the Service Agreement and (ii) that the daily business activities of Zhongchao will have a material impact on Zhongchao’s ability to pay the payables to the WFOE or its affiliates, the Shareholders agree that, unless required by the WFOE:

 

(a) 不得提出或投票赞成任何股东决议、或以其他方式要求众巢医学向其任何股东分配任何利润、资金、资产或财物;及

 

They shall not put forward, or vote in favor of, any shareholder resolution to, or otherwise request Zhongchao to, distribute any profits, funds, assets or property to the Shareholders of Zhongchao; and

 

5 / 17

 

 

(b) 不得提出或投票赞成任何股东决议、或以其他方式要求众巢医学就股东所持的股权分派任何股息或进行其他方式的分配;但若众巢医学向股东进行股息分配或以 其他方式进行分配,股东应于分配发生时立即且无条件向外商独资企业支付或转让其作为众巢医学的股东从众巢医学获得的任何股息或其他分配,并应在未经外商独资企业事先书面同意便向股东派发股息或进行其他分配的情况下承担该等股息与分配转让或支付给外商独资企业所产生的一切税费(包括外商独资企业被征收的税费)。

 

They shall not put forward, or vote in favor of, any shareholder resolution to, or otherwise request Zhongchao to, issue any dividends or other distributions with respect to the equity interest of Zhongchao held by the Shareholders; provided, however, if any dividends or other distributions are distributed to the Shareholders by Zhongchao, the Shareholders shall immediately and unconditionally pay or transfer to the WFOE any and all dividends or other distributions in whatsoever form obtained from Zhongchao as shareholders of Zhongchao at the time such distributions arise, and the Shareholders shall bear any and all taxes and fees with respect to such transfer of dividends and distributions to the WFOE (including the taxes and fees imposed on the WFOE) in the event such dividends or distributions are paid to the Shareholders without the WFOE’s prior written consent.

 

4. 转让

 

Assignments

 

未获外商独资企业的事先书面同意,股东和众巢医学不得向任何第三方转让其各自在本协议项下的权利和义务。股东和众巢医学在此共同同意,外商独资企业可以其完全自主判断自行转让其在本协议下的权利和义务,且仅需向众巢医学和股东发出书面通知。

 

The Shareholders and Zhongchao shall not assign their respective rights and obligations under this Agreement to any third party without the prior written consent of the WFOE. The Shareholders and Zhongchao hereby jointly agree that the WFOE may assign its rights and obligations under this Agreement as the WFOE may decide at its sole discretion and such transfer shall only be subject to a written notice sent to Zhongchao and the Shareholders.

 

本协议规定的权利和义务对各方的受让人、继承人、配偶、监护人、债权人或者任何其他有权对众巢医学之股权主张权利或者利益的其他人具有法律约束力,且无论该等权利和义务的转让是由接管、重组、继承、转让、死亡、丧失行为能力、破产、离婚或其他原因导致。

 

Rights and obligations under this Agreement shall be legally binding upon any assignees, successors, spouse, guardians and creditors of the Parties hereof or any other person that may be entitled to assume rights and interests in the equity interest of Zhongchao, no matter such assignment of obligations and rights is caused by takeover, restructuring, succession, assignment, death, incapacity, bankruptcy, divorce or any other reason.

 

5. 完整协议和协议修改

 

Entire Agreement and Amendment to Agreement

 

5.1 本协议及本协议中明确提及或包含的全部约定和/或文件构成关于本协议标的事项的完整协议,并取代各方此前就本协议标的事项达成的所有口头约定、合同、谅解和交流。

 

This Agreement and all agreements and/or documents mentioned or included explicitly by this Agreement constitute the complete agreement with respect to the subject matter of this Agreement and shall supersede any and all prior oral agreements, contracts, understandings and communications made by the Parties with respect to the subject matter of this Agreement.

 

6 / 17

 

 

5.2 对本协议的任何修改应以书面方式作出,并仅在本协议各方签署后方生效。由各方正式签署的修改协议或补充协议构成本协议的组成部分,与本协议具有同等法律效力。

 

Any modification of this Agreement shall be made in a written form and shall only become effective upon execution by all Parties of this Agreement. Modifications and supplements to this Agreement duly executed by the Parties shall be parts of this Agreement and shall have the same legal effect as this Agreement.

 

6. 陈述和保证

 

Representations and Warranties

 

6.1 外商独资企业特此作出如下陈述和保证:

 

The WFOE hereby represents and warrants as follows:

 

(a) 其是依照中国法律正式注册设立并有效存续的一家外商独资企业;

 

It is a wholly foreign-owned enterprise duly incorporated and validly existing under PRC law;

 

(b) 其于公司权力和营业范围之内签署并履行本协议。其已采取必要的公司行为且获得适当授权,并已从第三方和政府部门获得必要的同意及批准。外商独资企业签署并履行本协议不会违反法律或对其有约束力的合同;及

 

Its execution and performance of this Agreement are within its corporate power and business scope. It has taken necessary corporate actions and obtained appropriate authorizations, and has obtained the necessary consents and approvals from any third parties and government agencies. Its execution and performance of this Agreement do not violate the laws and contracts binding upon it; and

 

(c) 本协议一经签署即构成对外商独资企业合法、有效、有约束力的义务,并依本协议之条款可对其强制执行。

 

Upon execution, this Agreement will constitute a legal, valid and binding obligation of the WFOE enforceable against the WFOE in accordance with its terms.

 

6.2 众巢医学特此作出如下陈述和保证:

 

Zhongchao hereby represents and warrants as follows:

 

(a) 其是依照中国法律正式注册设立并有效存续的法人;

 

It is a legal person duly incorporated and validly existing under PRC law;

 

7 / 17

 

 

(b) 其于公司权力和营业范围之内签署并履行本协议。其已采取必要的公司行为且获得适当授权,并已从第三方和政府部门获得必要的同意及批准。其签署并履行本 协议不会违反法律或对其有约束力的合同;及

 

Its execution and performance of this Agreement are within its entity power and business scope. It has taken necessary entity actions and obtained appropriate authorizations, and has obtained the necessary consents and approvals from any third parties and government agencies. Its execution and performance of this Agreement do not violate the laws and contracts binding upon it; and

 

(c) 本协议一经签署即构成对其合法、有效、有约束力的义务,并依本协议之条款可对其强制执行。

 

Upon execution, this Agreement will constitute a legal, valid and binding obligation of Zhongchao enforceable against Zhongchao in accordance with its terms.

 

6.3 股东特此作出如下陈述和保证:

 

The Shareholders hereby represents and warrants as follows:

 

(a) 其于本协议签订之日,合法有效的拥有众巢医学的股权,有充分的权利和授权签署本协议。其签署并履行本协议不会违反法律或对其有约束力的合同;及

 

It has a valid and effective right to hold the shares of Zhongchao at the date of this Agreement and has full rights and authorizations to enter into this Agreement. Its execution and performance of this Agreement do not violate the laws and contracts binding upon it; and

 

(b) 本协议一经签署即构成对其合法、有效、有约束力的义务,并依本协议之条款可对其强制执行。

 

Upon execution, this Agreement will constitute a legal, valid and binding obligation of the Shareholders enforceable against the Shareholders in accordance with its terms.

 

7. 保密

 

7.1 各方承认,各方就本协议交换的任何口头或书面信息均属于保密信息。每一方应对上述全部信息保密,在未取得其他方的书面同意前,不得向任何第三方披露任何相关信息,但下述情况除外:(a)该信息已经或将被公众所知(但不是因为接受一方的违约披露导致的);(b)按照适用法律、法规或证券交易所的要求披露的;或(c)任何一方需要向其法律顾问、财务顾问、董事或高级管理人员披露的有关本协议项下拟定交易的信息,且该法律顾问、财务顾问、董事或高级管理人员受与本款规定相类似的保密义务的制约。如任何一方聘用的任何职员或代理机构披露保密信息,将被视为该方披露了该保密信息并因此承担违约责任。本款规定将在本协议因任何原因终止后持续有效。

 

The Parties acknowledge that any oral or written information exchanged among them with respect to this Agreement is confidential information. Each Party shall maintain the confidentiality of all such information, and without obtaining the written consent of other Parties, it shall not disclose any relevant information to any third parties, except in the following circumstances: (a) such information is or will be in the public domain (provided that this is not the result of a public disclosure by the receiving party); (b) information disclosed as required by applicable laws or regulations or rules of any securities exchange; or (c) information required to be disclosed by any Party to its legal counsel, financial advisor, directors or senior management officers regarding the transaction contemplated hereunder, provided that such legal counsel, financial advisor, directors or senior management officers is also bound by confidentiality duties similar to the duties set out in this section. Disclosure of any confidential information by the staff members or agency hired by any Party shall be deemed disclosure of such confidential information by such Party, which Party shall be held liable for breach of this Agreement. This Section shall survive the termination of this Agreement for any reason.

 

8 / 17

 

 

7.2 各方同意本协议终止或失效时,本条仍然有效。

 

The Parties agree that this section shall remain survive the termination or expiration of this Agreement.

 

8. 管辖法律

 

Governing Law

 

本协议受中国法律管辖且据其进行解释。

 

This Agreement shall be construed in accordance with and governed by the laws of China.

 

9. 争议解决

 

Dispute Resolution

 

因本协议产生或与本协议相关的任何争议或主张应由各方通过友好协商的方式解决。如果各方未能解决争议,应将争议提交到上海国际经济贸易仲裁委员会(“仲裁委”),由仲裁会按照申请仲裁时有效的仲裁委仲裁规则经由仲裁解决。仲裁地为上海,仲裁语言为中文。只用一名仲裁员仲裁,该仲裁员由仲裁委指定。仲裁裁决具终局性且对各方都有约束力。

 

Any dispute or claim arising out of or in connection with or relating to this Agreement shall be resolved by the Parties in good faith through negotiations. In case no resolution can be reached by the Parties, such dispute shall be submitted to the Shanghai International Economic and Trade Arbitration Commission (the “Arbitration Commission”) for arbitration in accordance with its rules of arbitration in effect at the time of applying for such arbitration and the place of arbitration shall be in Shanghai, and the language of arbitration shall be Chinese. The arbitration tribunal shall be composed of only one arbitrator, which shall be appointed by the arbitration commission. The arbitral award shall be final and binding upon all Parties.

 

在争议解决和仲裁程序进行过程中,除了本协议正在仲裁的事宜以外,各方应在实际可行的前提下继续履行本协议。每一方应自行承担为解决任何争议而发生的费用,但仲裁费应由各方平均分担。

 

Throughout any dispute resolution and arbitration proceedings, the Parties shall continue to perform this Agreement, to the extent practical, with the exception of the matter that is under arbitration. Each Party shall be responsible for its own expenses in connection with resolving any Dispute, but the arbitration fees shall be shared equally.

 

9 / 17

 

 

10. 损害赔偿

 

Indemnities and Remedies

 

10.1 如一方存在以下情形,则该方应就该等情形给另一方造成的损失、损害、责任、被索赔损失等(包括合理的律师费,“损失”)依照另一方的要求立即予以赔偿,以使另一方免受损失:(1)该一方在本协议中所作的任何陈述或保证不真实、不准确或不完整,或者(2)该一方违反了其在本协议中所作的任何陈述或保证,或者(3)该一方违反了其在本协议中任何约定或承诺;但如果另一方遭受的损失系由于该另一方或该另一方的董事、管理人员、雇员或者代理人自身的故意行为不当、违反法律、违约行为、重大过失等原因造成的,则违约方无需对另一方予以赔偿。

 

Either Party shall forthwith on demand indemnify and hold harmless the other Party against any claim, loss, liability or damage (including reasonable legal fees, “Loss”) which the other such Party shall suffer due to any of the following circumstances: (i) any of the representations or warranties herein made by such Party is untrue, inaccurate or incomplete, or (ii) such Party breaches any of its representations or warranties herein, or (iii) such Party breaches any covenant or undertaking herein; provided that neither Party shall be liable to indemnify the other Party for any Loss to the extent that such Loss arises from the willful misconduct, breach of applicable law, regulation or contractual obligation or from the material negligence of the other Party or its directors, officers, employees, or agents.

 

10.2 各方同意本协议终止或失效时,本条仍然有效。

 

The Parties agree that this section shall remain survive the termination or expiration of this Agreement.

 

11. 生效日和期限

 

Effective Date and Term

 

11.1 本协议应于文首所载日期签署并生效。

 

This Agreement shall be signed and take effect as of the date first set forth above.

 

11.2 本协议在众巢医学存续期间持续有效,除非根据第12条规定终止。

 

This Agreement shall remain effective as long as Zhongchao exists unless terminated as provided in Section 12.

 

12. 终止

Termination

 

12.1 股东和众巢医学均不得终止本协议。本协议在以下任何情况下终止:(1)外商独资企业可随时以提前三十(30)天书面通知众巢医学和股东的方式终止本协议;(2)根据《独家购股权协议》,股东持有的众巢医学之股权已转让给外商独资企业和/或外商独资企业指定的第三方,本协议于该等转让完成时终止。

 

Neither of the Shareholders and Zhongchao shall have the right to terminate this Agreement. This Agreement shall be terminated (i) by the WFOE at any time with thirty (30) days advance written notice to Zhongchao and the Shareholders; or (ii) upon the transfer of the equity interest held by the Shareholders to the WFOE and/or a third party designated by the WFOE pursuant to the Exclusive Option Agreement, this Agreement shall be terminated on the day of completion of this transfer.

 

10 / 17

 

 

13. 通知

 

Notices

 

13.1 任何一方按本协议规定发出的通知或其他通信应以英文或中文书写,并可以专人递送、挂号邮寄、邮资预付邮寄、或受承认的专递服务或发送传真的形式发送到有关各方不时指定的收件地址。通知被视为实际送达的日期,应按如下方式确定:(a)专人递送的通知,专人递送当日即视为已实际送达;(b)用信函发出的通知,则在邮资付讫的航空挂号信寄出日(依邮戳为准)后的第十(10)天,即视为已实际送达,或在送交专递服务公司后的第四(4)天,即视为已实际送达;以及(c)用传真发送的通知,在有关文件的传送确认单上所显示的接收时间,即视为已实际送达。

 

Notices or other communications required to be given by any party pursuant to this Agreement shall be written in English and Chinese and delivered personally or sent by registered mail or postage prepaid mail or by a recognized courier service or by facsimile transmission to the address of each relevant party as specified by such party from time to time. The date when a notice is deemed to be duly served shall be determined as follows: (a) a notice delivered personally is deemed duly served upon delivery; (b) a notice sent by mail is deemed duly served on the tenth (10th) day after the date when the postage prepaid registered airmail is posted (as evidenced by the postmark), or on the fourth (4th) day after the date when the notice is delivered to an internationally-recognized courier service agency; and (c) a notice sent by facsimile transmission is deemed duly served upon receipt as evidenced by the time shown in the transmission confirmation for the relevant documents.

 

14. 可分割性

 

Severability

 

如果本协议项下的任何条款因与有关法律不一致而无效或不可执行,则该条款仅在有关法律的管辖范围之内被视为无效或不可执行,并且本协议其他条款的有效性,合法性和可强制执行性不受其影响。

 

If any provision of this Agreement is judged to be invalid or unenforceable because it is inconsistent with applicable laws, such invalidity or unenforceability shall be only with respect to such laws, and the validity, legality and enforceability of the other provisions hereof shall not be affected.

 

15. 转让

 

Assignment

 

15.1 未经外商独资企业事先书面同意,众巢医学和股东不得将其在本协议项下的权利和义务转让给任何第三方。

 

Zhongchao and the Shareholders shall not assign any of its rights or obligations under this Agreement to any third party without the prior written consent of the WFOE.

 

11 / 17

 

 

15.2 众巢医学和股东在此同意,外商独资企业可转让其在本协议项下的权利和义务。外商独资企业仅需就该转让向众巢医学和股东发出书面通知。

 

Zhongchao and the Shareholders hereby agrees that the WFOE may assign its rights and obligations under this Agreement, only subject to a written notice to Zhongchao and the Shareholders.

 

15.3 本协议的条款和条件应为当事方各自的继承人和经许可的受让人之利益而生效,并应约束当事方各自的继承人和受让人。除非本协议明示规定,本协议的任何规定(明示和默示的)均不意图赋予除本协议当事方或其各自继承人和受让人之外的任何他方本协议项下或源于本协议的任何权利、救济、义务、或责任。

 

The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the Parties. Save as expressly provided in this Agreement, nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement.

 

16. 文本

Counterparts

 

本协议由协议各方签署四(4)份正本,所有正本具有同等法律效力。

 

This Agreement shall be executed in four (4) originals. All originals shall have the same legal effect.

 

17. 语言

Languages

 

本协议以英文和中文书就,英文文本和中文文本具有同等法律效力。若英文文本和中文文本有任何不一致的约定,以中文文本的相应内容为准。

 

This Agreement is written in English and Chinese, both English and Chinese language versions of this Agreement shall have equal validity. In case of any discrepancy between the English version and the Chinese version, the Chinese version shall prevail.

 

[后附签字页Signature Pages Follow]

 

12 / 17

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

 

北京众巢众行科技有限公司

 

Beijing Zhongchao Zhongxing Technology Co., Ltd.

 

授权代表(Authorized Representative):/s/ Weiguang Yang

 

13 / 17

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

 

众巢医学科技(上海)有限公司

 

Zhongchao Medical Technology (Shanghai) Co., Ltd.

 

授权代表(Authorized Representative):/s/ Weiguang Yang.

 

14 / 17

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

 

杨伟光

 

Weiguang Yang

 

签字/Signature:/s/ Weiguang Yang.

 

15 / 17

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

 

上海行众投资管理合伙企业(有限合伙)

 

Shanghai Xingzhong Investment Management LP, Ltd.

 

授权代表(Authorized Representative):/s/ Weiguang Yang.

 

16 / 17

 

 

SCHEDULE 1

附件1

 

Shareholders

股东

 

序号

No.

 

姓名

Name

 

证件号码/统一信用代码

No.

1.  

杨伟光

Weiguang Yang

  362227198206170314
2.  

上海行众投资管理合伙企业(有限合伙)

Shanghai Xingzhong Investment Management LP, Ltd.

  913101143584694449

 

 

17 / 17

 

Exhibit 10.5

 

独家购股权协议

 

EXCLUSIVE OPTION AGREEMENT

 

本独家购股权协议(“本协议”)于2020年 9 10 日由以下各方在上海订立:

  

This Exclusive Option Agreement(this “Agreement”)is entered into in Shanghai as of September 10th , 2020; by and among the following parties:

  

(1) 北京众巢众行科技有限公司(外商独资企业”),一家根据中华人民共和国(“中国”)法律在中国上海注册成立的外商独资企业;

 

Beijing Zhongchao Zhongxing Technology Co.,Ltd. (the “WFOE”), a wholly foreign-owned enterprise registered in Beijing, the People’s Republic of China (“China” or “PRC”), under the laws of China;

 

2) 众巢医学科技(上海)有限公司(“众巢医学”),一家根据中国法律在中国上海注册成立的内资公司;和

  

Zhongchao Medical Technology (Shanghai) Co., Ltd. (“Zhongchao”), a domestic company registered in Shanghai, China, under the laws of China; and

 

(3) 在附件1列明的每一方(以下这样的个人单独称为“一名股东”,合称为“股东”)

 

Each of the parties listed under Schedule 1 (each, “a Shareholder” and collectively, the “Shareholders”)

 

(以上外商独资企业、众巢医学和每一位股东单独称为“一方”,合称为“各方”)。

 

(Each of the WFOE, Zhongchao and each of the Shareholders, a “Party”, and collectively the “Parties”).

 

序言

 

RECITALS

 

(A) 鉴于,股东持有众巢医学100%的股权;

 

WHEREAS, the Shareholders hold100% equity interest in Zhongchao.

 

(B) 鉴于,外商独资企业和众巢医学于2019年814日签署了一份《独家服务总协议》;

 

WHEREAS, the WFOE and Zhongchao entered into a master exclusive service agreement dated on August 14, 2019;

 

(C) 鉴于,外商独资企业、众巢医学以及股东于2020年 910 日订立了一份《业务合作协议》;

 

WHEREAS, the WFOE, Zhongchao and the Shareholders entered into a business cooperation agreement dated September 10th , 2020;

 

1 / 30 

 

 

(D) 鉴于,作为为众巢医学的正常经营持续提供服务的对价,外商独资企业要求股东通过本协议向外商独资企业授予购买股东持有的众巢医学全部或部分股权的独家权利,由外商独资企业或外商独资企业指定方行使,且股东同意授予外商独资企业独家购买众巢医学全部或部分股权的权利。

 

WHEREAS, as the consideration for the WFOE and its affiliates to provide Zhongchao with services necessary for their business operation, the WFOE has requested the Shareholders to grant the WFOE an exclusive option through this Agreement which can be exercised by the WFOE or the WFOE’s designee, and the Shareholders have agreed to grant such exclusive option to purchase all or part of the equity interest held by the Shareholders in Zhongchao.

 

(E) 有鉴于此,基于本协议包含的前提、陈述、保证、承诺和约定,本协议各方愿意受其法律约束并约定如下:

 

NOW, THEREFORE, in consideration of the premises and the representations, warranties, covenants and agreements herein contained, and intending to be legally bound hereby, the Parties hereby agree as follows:

  

协议

 

AGREEMENT

 

1. 标的股权

 

Target Equity Interest

 

1.1 在下述情况下,外商独资企业有权要求股东向外商独资企业或外商独资企业指定的第三方(“被指定方”)转让股东持有的众巢医学的全部或部分(以外商独资企业的具体要求为准)股权(“标的股权”),且股东应按照外商独资企业的要求向外商独资企业和/或被指定方转让标的股权(“股权转让选择权”),除外商独资企业和/或被指定方外,任何其他第三方均不得享有股权转让选择权:

 

The WFOE shall have the right to require the Shareholders to transfer any and all of the equity interest of Zhongchao the Shareholders hold (the “Target Equity Interest”) to the WFOE and/or a third party designated by the WFOE (the “Designee”), in whole or in part, subject to the WFOE’s specific requirements (“Equity Interest Transfer Option”),and the Shareholders shall transfer the Target Equity Interest to the WFOE and/or its Designee, who shall have exclusive rights over the Equity Interest Transfer Option, in accordance with the WFOE’s requirements under the following circumstances:

 

1.1.1 中国法律和行政法规允许外商独资企业和/或其被指定方合法拥有全部或部分标的股权;或

 

Where the WFOE and/or its Designee can legally own all or part of the Target Equity Interest under the laws and administrative regulations of China; or

 

2 / 30 

 

 

1.1.2 外商独资企业以其完全自主判断认为适宜或必要的任何其他情形。

 

Any other circumstances deemed as appropriate or necessary by the WFOE in its sole discretion.

 

1.2 外商独资企业有权随时行使其全部或部分股权购买选择权,取得全部或部分标的股权,且行权次数不限。

 

The WFOE shall have the right to exercise its purchase right of equity in whole or in part and to acquire the Target Equity Interest in whole or in part without any limit at any time and from time to time.

 

1.3 外商独资企业有权指定任何第三方取得全部或部分标的股权,股东不得拒绝,并应按照外商独资企业的要求向该等被指定方转让全部或部分标的股权。

 

The WFOE may designate any third party to acquire the Target Equity Interest in whole or in part and the Shareholders shall not refuse and shall transfer the Target Equity Interest in whole or in part to such Designee as requested by the WFOE.

 

1.4 按本协议向外商独资企业或其被指定方转让标的股权以前,未经外商独资企业事先书面同意,股东不得向任何第三方转让标的股权或其任何部分。

 

Prior to the transfer of the Target Equity Interest to the WFOE or its Designee according to this Agreement, the Shareholders shall not transfer the Target Equity Interest or any portion thereof to any third party without the WFOE’s prior written consent.

 

2. 程序

 

Procedures

 

2.1 在履行本协议时,股东应按照本协议附件二规定的格式签署《股权转让协议》,并将该文件交付给外商独资企业。

 

Concurrent with the execution of this Agreement, the Shareholders shall execute and deliver to the WFOE the Equity Interest Transfer Agreement in the format set forth in Schedule 2 attached hereto.

 

2.2 若外商独资企业根据上述第1.1条规定决定行使股权转让选择权,应向众巢医学和股东发出书面通知,其中说明拟受让标的股权的比例和受让方的身份(“股权购买通知”)。众巢医学和股东应在股权购买通知之日起的七(7)日内,为办理上述股权转让的登记过户提供必要的全部资料和文件。

 

If the WFOE decides to exercise the Equity Interest Transfer Option pursuant to Section 1.1 hereinabove, it shall send written notice to Zhongchao and the Shareholders which specifies the proportion of the Target Equity Interest to be acquired and identifies the transferee (the “Equity Interest Purchase Notice”). Zhongchao and the Shareholders shall furnish all materials and documents necessary for the registration of said equity interest transfer within seven (7) days after the date of Equity Interest Purchase Notice;

 

3 / 30 

 

 

2.3 在行使股权转让选择权时,若不止一位股东持有众巢医学的股权,则本协议项下的股东 和众巢医学应促使众巢医学的其他股东做出书面说明,同意向外商独资企业和/或被指定方转让标的股权,并放弃与之相关的任何优先购买权;

 

If at the time of exercising the Equity Interest Transfer Option, more than one Shareholder hold equity interest in Zhongchao, each Shareholder and Zhongchao shall cause such other Shareholders to provide their written consent to the transfer of the Target Equity Interest to the WFOE and/or the Designee(s) and to waive any preemptive right related thereto;

 

2.4 众巢医学和股东应就按本协议和股权购买通知进行的各次标的股权转让,促使股东和外商独资企业和/或各被指定方(依实际情况而定)之间签署一份股权转让协议;

 

Zhongchao and the Shareholders shall cause an Equity Interest Transfer Agreement to be duly executed with respect to each transfer to the WFOE and/or each Designee (whichever is applicable), in accordance with the provisions of this Agreement and the Equity Interest Purchase Notice regarding the Target Equity Interest;

 

2.5 有关各方应签署全部必要的合同、协议或文件,取得全部必要的政府证照和批文,并采取全部必要的行动,从而向外商独资企业和/或被指定方转让标的股权的所有权(不受任何担保权益的限制),并促使外商独资企业和/或被指定方成为标的股权的登记所有人。就本条和本协议而言,“担保权益”包括担保、抵押、第三方权利或权益、股票期权、购买权、优先受让权、抵销权、所有权留置或其他担保安排,但不包括本协议和股权质押协议设立的任何担保权益。

 

The relevant Parties shall execute all necessary contracts, agreements or documents, obtain all necessary government licenses and permits and take all necessary actions to transfer valid ownership of the Target Equity Interest to the WFOE and/or the Designee(s), unencumbered by any security interests, and cause the WFOE and/or the Designee(s) to become the registered owner(s) of the Target Equity Interest. For the purpose of this Section and this Agreement, “security interests” shall include securities, mortgages, third party’s rights or interests, any stock options, acquisition right, right of first refusal, right to offset, ownership retention or other security arrangements, but shall be deemed to exclude any security interest created by this Agreement and the Equity Interest Pledge Agreement.

 

3. 转让价款

 

Transfer Price

 

3.1 标的股权的全部转让价款为前述股权转让时中国法律和行政法规允许的最低价格(“转让价格”)。如果标的股权分批转让,则应按照转让标的股权的比例确定相应的转让价款金额。股东因转让标的股权而获得的全部转让价款以及任何其他相关收益应在取得后立即无偿转交给外商独资企业或外商独资企业指定的实体。

 

The total transfer price for the Target Equity Interest shall be the lowest price allowable under PRC laws and administrative regulations at the time of said transfer (“Transfer Price”). If the Target Equity Interest are transferred in installments, the due transfer price for each installment shall be determined in accordance with the proportion of Target Equity Interest under said transfer. The Shareholders shall transfer the Transfer Price and affiliated benefits to the WFOE or the entity designated by the WFOE at nil consideration immediately after receiving the Transfer Price and affiliated benefits.

 

4 / 30 

 

 

3.2 转让标的股权产生的全部税费、费用和杂费应由相关各方按照中国法律各自承担。

 

All the taxes, fees and expenses arising from the transfer of the Target Equity Interest shall be borne by each relevant Party respectively in accordance with the Laws of China.

 

4. 承诺

 

Covenants

 

4.1 众巢医学和股东的承诺

 

Covenants of Zhongchao and the Shareholders

 

股东(作为众巢医学的股东)和众巢医学特此承诺如下:

 

The Shareholders (as the shareholders of Zhongchao) and Zhongchao hereby covenant as follows:

 

4.1.1 未经外商独资企业事先书面同意,其不会通过任何形式补充、变更或修改众巢医学的公司章程或其他组织性文件,不会增减众巢医学的注册资本,也不会通过其他方式变更众巢医学的注册资本结构;

 

Without the prior written consent of the WFOE, they shall not in any manner supplement, change or amend the articles of association or other documents of Zhongchao, increase or decrease its registered capital, or change the structure of its registered capital in other manners;

 

4.1.2 其应谨慎、有效地经营众巢医学的公司业务和处理其事务,按照良好的财务和商业标准及实务维持众巢医学的存续;

 

They shall maintain Zhongchao’s corporate existence in accordance with good financial and business standards and practices by prudently and effectively operating its business and handling its affairs;

 

4.1.3 未经外商独资企业事先书面同意,其不会在本协议签署后通过任何方式出售、转让、抵押或处置众巢医学的任何资产(除在日常经营过程中产生的资产处置)或众巢医学业务或收入中的法定或受益权益,也不会允许设置任何相关的担保权益,或其他权利负担;

 

Without the prior written consent of the WFOE, they shall not at any time following the date hereof, sell, transfer, mortgage or dispose of in any manner any assets of Zhongchao (except in the ordinary course of business), or legal or beneficial interest in the business or revenues of Zhongchao, or allow the encumbrance thereon of any security interest or any other encumbrance;

 

4.1.4 未经外商独资企业事先书面同意,其不会发生、继承、担保或承受任何债务,但不包括在正常业务过程中发生的债务;

 

Without the prior written consent of the WFOE, they shall not incur, inherit, guarantee or assume any debt, except for debts incurred in the ordinary course of business;

 

5 / 30 

 

 

4.1.5 其应在经营众巢医学全部业务的正常运营过程中,一直保持众巢医学的资产价值,不得采取任何可能影响众巢医学业务状况和资产价值的任何行为/不作为;

 

They shall always operate all of Zhongchao’s businesses during the ordinary course of business to maintain the asset value of Zhongchao and refrain from any action/omission that may adversely affect Zhongchao’s operating status and asset value;

 

4.1.6 未经外商独资企业事先书面同意,其不会促使众巢医学签署任何重大合同,但在正常业务过程中签署的除外(就本段而言,重大合同的标准由外商独资企业自行判断);

 

Without the prior written consent of the WFOE, they shall not cause Zhongchao to execute any material contract, except the contracts executed in the ordinary course of business (for purpose of this subsection, the WFOE may define a material contract at its sole discretion);

 

4.1.7 未经外商独资企业事先书面同意,其不会促使众巢医学向任何人提供任何贷款或信贷,但正常业务过程中提供的除外;

 

Without the prior written consent of the WFOE, they shall not cause Zhongchao to provide any person with any loan or credit other than in the course of ordinary business;

 

4.1.8 其应在外商独资企业提出要求时提供有关众巢医学业务经营和财务状况的相关资料;

 

They shall provide the WFOE with information on Zhongchao’s business operations and financial condition at WFOE’s request;

 

4.1.9 如外商独资企业要求,其应为众巢医学的资产和业务从符合外商独资企业要求的保险公司处购买并持有保险,保险金额和险种应符合同类公司购买的金额和种类;

 

If requested by the WFOE, they shall procure and maintain insurance in respect of Zhongchao’s assets and business from an insurance carrier acceptable to the WFOE, at an amount and type of coverage typical for companies that operate similar businesses;

 

4.1.10 未经外商独资企业事先书面同意,其不会促使或允许众巢医学与任何人进行合并或整合或向任何人进行收购或投资,或与他方组成合伙、合营企业或者其他类似性质的经济组织;

 

Without the prior written consent of the WFOE, they shall not cause or permit Zhongchao to merge, consolidate with, acquire or invest in any person, or formation of any partnership, joint venture or other similar entity with a third party;

 

6 / 30 

 

 

4.1.11 如发生或可能发生与众巢医学的资产、业务或收入相关的任何诉讼、仲裁或行政程序,其应立即通知外商独资企业;

 

They shall immediately notify the WFOE of the occurrence or possible occurrence of any litigation, arbitration or administrative proceedings relating to Zhongchao’s assets, business or revenue;

 

4.1.12 为保持众巢医学对其全部资产的所有权,其应签署全部必要或适当的文件,采取全部必要或适当的行为,提出全部必要或适当的控告,或针对全部索赔提出必要和适当的抗辩;

 

To maintain the ownership by Zhongchao of all of its assets, they shall execute all necessary or appropriate documents, take all necessary or appropriate actions and file all necessary or appropriate complaints or raise necessary and appropriate defenses against all claims;

 

4.1.13 未经外商独资企业事先书面同意,其应确保众巢医学不会通过任何方式向股东分配股息,但在外商独资企业书面要求时,众巢医学应立即向股东分配全部或部分可分配利润,然后再由股东立即并无条件地将上述分配支付或转移至外商独资企业;

 

Without the prior written consent of the WFOE, they shall ensure that Zhongchao shall not in any manner distribute dividends to its shareholder(s), provided that upon the WFOE’s written request, Zhongchao shall immediately distribute part or all distributable profits to its shareholder(s) who shall in turn immediately and unconditionally pay or transfer to the WFOE any such distribution;

 

4.1.14 在外商独资企业要求时,其应任命外商独资企业指定的任何人担任众巢医学的董事和/或执行董事;

 

At the request of the WFOE, they shall appoint any persons designated by the WFOE as the directors and/or executive director of Zhongchao;

 

4.1.15 其应促使众巢医学的股东会及董事会通过与外商独资企业的指示一致的股东会决议及董事会决议;

 

They shall cause the meeting of shareholders and the board of directors of Zhongchao to pass shareholders’ resolutions and board resolutions in accordance with the instruction of the WFOE;

 

4.1.16 除非中国法律强制要求,未经外商独资企业书面同意,众巢医学不得解散或清算。

 

Unless otherwise mandatorily required by PRC laws, Zhongchao shall not be dissolved or liquated without prior written consent by the WFOE.

 

7 / 30 

 

 

4.2 有关众巢医学之股权的承诺

 

Covenants regarding Equity Interest in Zhongchao

 

股东特此承诺如下:

 

Each Shareholder hereby covenants as follows:

 

4.2.1 未经外商独资企业事先书面同意,任一股东不会通过任何方式出售、转让、抵押或处置标的股权的任何法定或受益权益,也不会允许在其上设置任何其他担保权益,但按照股权质押协议对标的股权进行的质押除外;

 

Without the prior written consent of the WFOE, any Shareholder shall not sell, transfer, mortgage or dispose of in any other manner any legal or beneficial interest in the Target Equity Interest or allow the encumbrance thereon of any security interest, except for the pledge placed on the Target Equity Interest in accordance with the Equity Interest Pledge Agreement;

 

4.2.2 股东应促使众巢医学的股东会(为本协议之目的,除另有明确约定,“股东会”包含“股东大会”之意义)会议和/或董事会会议和/或执行董事在未经外商独资企业事先书面同意情况下,对以任何方式出售、转让、抵押或处置标的股权的任何法定或受益权益不予批准,也不允许在其上设置任何其他担保权益,但按照股权质押协议对标的股权进行的质押除外;

 

The Shareholder shall cause the shareholders’ meeting (as for the purpose of this Agreement, unless otherwise stipulated herein, “shareholders’ meetings” includes the meaning of “the general meeting”) the meeting and/or the board of directors’ meeting and/or the executive directors of Zhongchao not to approve the sale, transfer, mortgage or disposition in any other manner of any legal or beneficial interest in the Target Equity Interest or allow the encumbrance thereon of any security interest, without the prior written consent of the WFOE, except for the pledge placed on the Target Equity Interest in accordance with the Equity Interest Pledge Agreement;

 

4.2.3 股东应促使众巢医学的股东大会和/或董事和/或执行董事会议在未经外商独资企业事先书面同意情况下,对众巢医学与任何企业或其他经济组织的合并或整合,或对任何企业或其他经济组织进行收购或投资,或设立合资企业、合伙或者其他类似性质的经济组织,或以任何方式出售、转让、抵押或处置标的股权的任何法定或受益权益不予批准;

 

The Shareholder shall cause the shareholders’ meeting or the board of directors and/or the executive directors of Zhongchao not to approve the merger or consolidation with any enterprise or other entity, or the acquisition of or investment in any enterprise or other entity, and not to approve the sale, transfer, mortgage or disposition in any other manner of any legal or beneficial interest in the Target Equity Interest without the prior written consent of the WFOE;

 

8 / 30 

 

 

4.2.4 如发生或可能发生与标的股权相关的任何诉讼、仲裁或行政程序,股东应立即通知外商独资企业;

 

The Shareholder shall immediately notify the WFOE of the occurrence or possible occurrence of any litigation, arbitration or administrative proceedings relating to the Target Equity Interest;

 

4.2.5 在外商独资企业要求时,股东应及时和无条件地促使标的股权的转让按本协议规定得到批准和完成;

 

At the request of the WFOE at any time, the Shareholder shall promptly and unconditionally cause the transfer of the Target Equity Interest to be approved and consummated as set forth in this Agreement;

 

4.2.6 为保持股东对众巢医学的所有权,股东应签署全部必要或适当的文件,采取全部必要或适当的行为,提出全部必要或适当的控告,或针对全部索赔提出必要和适当的抗辩;

 

To the extent necessary to maintain the Shareholder’s ownership in Zhongchao, the Shareholder shall execute all necessary or appropriate documents, take all necessary or appropriate actions and file all necessary or appropriate complaints or raise necessary and appropriate defenses against all claims;

 

4.2.7 在外商独资企业要求时,股东应任命外商独资企业指定的任何人担任众巢医学的董事和/或执行董事;

 

The Shareholder shall appoint any designee of the WFOE as the director and/or executive director of Zhongchao, at the request of the WFOE;

 

4.2.8 如股东从众巢医学获得任何利润、分红、股利、股息或清算所得,股东应在遵从中国法律的前提下将其及时赠予外商独资企业或外商独资企业指定的任何实体;和

 

The Shareholders shall promptly donate any profit, interest, dividend or proceeds of liquidation received from Zhongchao to the WFOE or any other entity designated by the WFOE to the extent permitted under applicable PRC laws; and

 

4.2.9 股东应严格遵守本协议以及股东、外商独资企业和众巢医学之间共同或单独签署的其他合同规定,履行其中的义务,不得进行任何可能影响上述协议和合同的有效性和可执行性的作为/不作为。若股东在本协议、或股权质押协议、或对外商独资企业授权的委托协议及授权委托书项下的股权还留存有任何权利,股东不得行使该等权利,除非按照外商独资企业的书面指示行事。

 

The Shareholder shall strictly abide by the provisions of this Agreement and other contracts jointly or separately executed by and among the Shareholder, the WFOE and Zhongchao, perform the obligations hereunder and thereunder, and refrain from any action/omission that may affect the effectiveness and enforceability hereof and thereof. To the extent that the Shareholder has any remaining rights with respect to the equity interest subject to this Agreement hereunder or under the Equity Interest Pledge Agreement or under the proxy agreement and power of attorney granted in favor of the WFOE, the Shareholder shall not exercise such rights except in accordance with the written instructions of the WFOE.

 

9 / 30 

 

 

5. 陈述和保证

 

Representations and Warranties

 

股东和众巢医学特此连带地向外商独资企业陈述和保证,截至本协议签署日和各标的股权转让日:

 

The Shareholders and Zhongchao hereby represent and warrant to the WFOE, jointly and severally, as of the date of this Agreement and each date of transfer of the Target Equity Interest, that:

 

5.1 其有权签署本协议和涉及标的股权转让的相关股权转让协议,且具有履行本协议和任何股权转让协议项下义务的能力;

 

The Shareholders and Zhongchao have the authority to execute and deliver this Agreement and any relevant Equity Interest Transfer Agreement concerning the Target Equity Interest to be transferred thereunder, and to perform their obligations under this Agreement and any Equity Interest Transfer Agreements;

 

5.2 签署和交付本协议或任何股权转让协议以及履行其项下的任何义务,不会:(1)导致违反任何相关的中国法律;(2)与众巢医学的公司章程、内部细则或其他组织文件抵触;(3)导致违反其订立或对其具有约束力的任何合同或文件,或构成该等合同或文件项下的违约;(4)导致违反向其发放的任何证照或许可的任何发放条件和/或持续有效的条件;及(5)导致向其发放的任何证照或许可被吊销、没收或附加额外条件;

 

The execution and delivery of this Agreement or any Equity Interest Transfer Agreements and the performance of any obligations under this Agreement or any Equity Interest Transfer Agreements: (i) do not cause any violation of any applicable laws of China; (ii) are not inconsistent with the articles of association, bylaws or other organizational documents of Zhongchao; (iii) do not cause the violation of any contracts or instruments to which they are a party or which are binding on them, or constitute any breach under any contracts or instruments to which they are a party or which are binding on them; (iv) do not cause any violation of any condition for the grant and/or continued effectiveness of any licenses or permits issued to any of them; and (v) do not cause the suspension or revocation of or imposition of additional conditions to any licenses or permits issued to any of them;

 

5.3 股东对标的股权拥有有效和可出售的所有权。除股权质押协议外,股东未对标的股权设置任何担保权益;

 

The Shareholders have good and merchantable title to the Target Equity Interest. Except for the Equity Interest Pledge Agreement, the Shareholders have not placed any security interest on the Target Equity Interest;

 

10 / 30 

 

 

5.4 众巢医学对其全部资产拥有有效和可出售的所有权,未对上述资产设置任何担保权益,但已向外商独资企业披露且已获得外商独资企业书面同意的担保权益除外;

 

Zhongchao has good and merchantable title to all of its assets, and has not placed any security interest on the aforementioned assets, except for encumbrance disclosed to the WFOE for which WFOE’s written consent has been obtained;

 

5.5 众巢医学无任何尚未偿还的债务,但不包括(1)在正常业务过程中发生的债务;和(2)已向外商独资企业披露且已获得外商独资企业书面同意的债务;及

 

Zhongchao does not have any outstanding debts, except for (i) debts incurred in the ordinary course of business; and (ii) debts disclosed to the WFOE for which WFOE’s written consent has been obtained; and

 

5.6 众巢医学已遵守有关兼并收购的全部中国法律法规。

 

Zhongchao has complied with all laws and regulations of China applicable to mergers and acquisitions.

 

6. 税务和费用

 

Taxes and Fees

 

在编制和签署本协议和股权转让协议,以及完成本协议和股权转让协议拟定的交易过程中,各方应支付依据中国法律征收或发生的全部转让和登记税费、支出和费用。

 

Each Party shall pay any and all transfer and registration tax, expenses and fees incurred thereby or levied thereon in accordance with the laws of China in connection with the preparation and execution of this Agreement and the Equity Interest Transfer Agreement, as well as the consummation of the transactions contemplated under this Agreement and the Equity Interest Transfer Agreement.

 

7. 保密

 

Confidentiality

 

7.1 各方承认,各方就本协议交换的任何口头或书面信息均属于保密信息。每一方应对上述全部信息保密,在未取得其他方的书面同意前,不得向任何第三方披露任何相关信息,但下述情况除外:(a)该信息已经或将被公众所知(但不是因为接受一方的违约披露导致的);(b)按照适用法律、法规或证券交易所的要求披露的;或(c)任何一方需要向其法律顾问、财务顾问、董事或高级管理人员披露的有关本协议项下拟定交易的信息,且该法律顾问、财务顾问、董事或高级管理人员受与本款规定相类似的保密义务的制约。如任何一方聘用的任何职员或代理机构披露保密信息,将被视为该方披露了该保密信息并因此承担违约责任。本款规定将在本协议因任何原因终止后持续有效。

 

The Parties acknowledge that any oral or written information exchanged among them with respect to this Agreement is confidential information. Each Party shall maintain the confidentiality of all such information, and without obtaining the written consent of other Parties, it shall not disclose any relevant information to any third parties, except in the following circumstances: (a) such information is or will be in the public domain (provided that this is not the result of a public disclosure by the receiving party); (b) information disclosed as required by applicable laws or regulations or rules of any securities exchange; or (c) information required to be disclosed by any Party to its legal counsel, financial advisor, directors or senior management officers regarding the transaction contemplated hereunder, provided that such legal counsel, financial advisor, directors or senior management officers is also bound by confidentiality duties similar to the duties set out in this section. Disclosure of any confidential information by the staff members or agency hired by any Party shall be deemed disclosure of such confidential information by such Party, which Party shall be held liable for breach of this Agreement. This Section shall survive the termination of this Agreement for any reason.

 

11 / 30 

 

 

7.2 各方同意本协议终止或失效时,本条仍然有效。

 

The Parties agree that this section shall remain survive the termination or expiration of this Agreement.

 

8. 转让

 

Assignment

 

8.1 未经外商独资企业事先书面同意,众巢医学和股东不得向任何第三方转让各自在本协议项下的任何权利或义务。

 

Zhongchao and the Shareholders shall not assign any of their respective rights or obligations under this Agreement to any third party without the prior written consent of the WFOE.

 

8.2 众巢医学和股东特此同意,外商独资企业可以其完全自主判断自行转让其在本协议项下的权利和义务,且仅需向众巢医学和股东发出转让本协议下权利义务的书面通知。

 

Zhongchao and the Shareholders hereby agree that the WFOE may assign its rights and obligations under this Agreement as the WFOE may decide at its sole discretion, and such assignment shall only be subject to a written notice sent to Zhongchao and the Shareholders.

 

8.3 本协议的条款和条件应为当事方各自的继承人和经许可的受让人之利益而生效,并应约束当事方各自的继承人和受让人。除非本协议明示规定,本协议的任何规定(明示和默示的)均不意图赋予除本协议当事方或其各自继承人和受让人之外的任何他方本协议项下或源于本协议的任何权利、救济、义务、或责任。

 

The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the Parties. Save as expressly provided in this Agreement, nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement.

 

9. 完整协议和协议修改

 

Entire Agreement and Amendment to Agreement

 

9.1 本协议及本协议中明确提及或包含的全部约定和/或文件构成有关本协议标的事项的完整 约定,并取代此前各方就本协议标的事项达成的全部口头约定、合同、谅解和交流。

 

This Agreement and all agreements and/or documents mentioned or included explicitly by this Agreement constitute the complete agreement with respect to the subject matter of this Agreement and shall substitute any and all prior oral agreements, contracts, understandings and communications made by the Parties with respect to the subject matter of this Agreement.

 

12 / 30 

 

 

9.2 对本协议的任何修改应以书面方式作出,并仅在本协议各方签署后生效。经各方正式签署的修改协议和补充协议构成本协议的组成部分,并与本协议具有同等法律效力。

 

Any modification of this Agreement shall be made in a written form and shall only become effective upon execution by all Parties of this Agreement. Modifications and supplements to this Agreements duly executed by the Parties shall be parts of this Agreement and shall have the same legal effect as this Agreement.

 

9.3 标的股权转让时,若根据当时有效的中国法律和行政法规有必要修改本协议附件二《股权转让协议》的格式,各方应友好协商依照中国法律和行政法规修改上述格式。

 

In the event that at the time of the Target Equity Interest transfer, it is necessary to modify the form of the “Equity Interest Transfer Agreement” set forth in Schedule 2 attached hereto pursuant to the then effective PRC laws and administrative regulations, the Parties shall make such modifications in good faith in compliance with PRC laws and administrative regulations.

 

9.4 附件是本协议的必要组成部分,与本协议的其他部分具有同等法律效力。

 

The Schedules are an integral part of this Agreement and have the same legal effects as the other parts of the Agreement.

 

10. 管辖法律

 

Governing Law

 

本协议依中国法律解释并受其管辖。

 

This Agreement shall be construed in accordance with and governed by the laws of China.

 

11. 争议解决

 

Dispute Resolution

 

因本协议产生或与本协议相关的任何争议或主张应由各方通过友好协商的方式解决。如果各方未能解决争议,应将争议提交到上海国际经济贸易仲裁委员会(“仲裁委”),由仲裁委按照申请仲裁时有效的仲裁委仲裁规则经由仲裁解决。仲裁地为上海,仲裁语言为中文。只用一名仲裁员仲裁,该仲裁员由仲裁委指定。仲裁裁决具终局性且对各方都有约束力。

 

Any dispute or claim arising out of or in connection with or relating to this Agreement shall be resolved by the Parties in good faith through negotiations. In case no resolution can be reached by the Parties, such dispute shall be submitted to the Shanghai International Economic and Trade Arbitration Commission(the “Arbitration Commission”) for arbitration in accordance with its rules of arbitration in effect at the time of applying for such arbitration and the place of arbitration shall be in Shanghai, and the language of arbitration shall be Chinese. The arbitration tribunal shall be composed of only one arbitrator, which shall be appointed by the arbitration commission. The arbitral award shall be final and binding upon all Parties.

 

13 / 30 

 

 

在争议解决和仲裁程序进行过程中,除了本协议正在仲裁的事宜以外,各方应在实际可行的前提下继续履行本协议。每一方应自行承担为解决任何争议而发生的费用,但仲裁费应由各方平均分担。

 

Throughout any dispute resolution and arbitration proceedings, the Parties shall continue to perform this Agreement, to the extent practical, with the exception of the matter that is under arbitration. Each Party shall be responsible for its own expenses in connection with resolving any Dispute, but the arbitration fees shall be shared equally.

 

12. 生效日和期限

 

Effective Date and Term

 

12.1 本协议于文首所载之日签署并生效。

 

This Agreement shall be signed and take effect as of the date first set forth above.

 

12.2 本协议在众巢医学存续期间将持续有效,除非根据第13条终止。

 

This Agreement shall remain effective as long as Zhongchao exists unless terminated as provided in Section 13.

 

13. 终止

 

Termination

 

13.1 众巢医学和股东均无权终止本协议。本协议在以下任何情况下终止:(1)外商独资企业可随时以提前三十(30)天书面通知众巢医学和股东的方式终止本协议;(2)根据本协议,股东持有的众巢医学之股权已全部转让给外商独资企业和/或其被指定方,则本协议于该等股权转让完成时终止。

 

Neither of the Shareholders and Zhongchao shall have the right to terminate this Agreement. This Agreement shall be terminated i) by the WFOE at any time with thirty (30) days advance written notice to Zhongchao and the Shareholders; or ii) upon the transfer of all the equity interest held by the Shareholders to the WFOE and/or its Designee pursuant to this Agreement, this Agreement shall be terminated on the day of completion of this transfer.

 

14 / 30 

 

 

14. 损害和赔偿

 

Indemnities and Remedies

 

14.1 如一方违反本协议,则该方应就违反本协议而给另一方造成的损失、损害、责任、被索赔损失等(“损失”)依照另一方的要求立即予以赔偿,但如果另一方遭受的损失系由于该另一方或该另一方的董事、管理人员、雇员或者代理自身的故意行为不当、违反法律、违约行为、重大过失等原因造成的,则违约方无需对另一方予以赔偿。

 

Either Party shall forthwith on demand indemnify the other Party against any claim, loss, liability or damage (“Loss”) which such Party shall incur as a consequence of any breach by the other Party of this Agreement provided that neither Party shall be liable to indemnify the other Party for any Loss to the extent that such Loss arises from the willful misconduct, breach of applicable law, regulation or contractual obligation or from the material negligence of the other Party or its directors, officers, employees, or agents.

 

14.2 各方同意本协议终止或失效时,本条仍然有效。

 

The Parties agree that this section shall survive the termination or expiration of this Agreement.

 

15. 通知

 

Notices

 

任何一方按本协议规定发出的通知或其他通信应以英文或中文语书写,并可以专人递送、挂号邮寄、邮资预付邮寄、或受承认的专递服务或发送传真的形式发送到有关各方不时指定的收件地址。通知被视为实际到达的日期,应按如下方式确定:(a)专人递送的通知,专人递送当日即视为已实际送达;(b)用信函发出的通知,则在邮资付讫的航空挂号信寄出日(依邮戳为准)后的第十(10)天,即视为已实际送达,或在送交专递服务公司后的第四(4)天,即视为已实际送达;以及(c)用传真发送的通知,在有关文件的传送确认单上所显示的接收时间,即视为已实际送达。

 

Notices or other communications required to be given by any party pursuant to this Agreement shall be written in English and Chinese and delivered personally or sent by registered mail or postage prepaid mail or by a recognized courier service or by facsimile transmission to the address of each relevant party as specified by such party from time to time. The date when a notice is deemed to be duly served shall be determined as follows: (a) a notice delivered personally is deemed duly served upon delivery; (b) a notice sent by mail is deemed duly served on the tenth (10th) day after the date when the postage prepaid registered airmail is posted (as evidenced by the postmark), or on the fourth (4th) day after the date when the notice is delivered to an internationally-recognized courier service agency; and (c) a notice sent by facsimile transmission is deemed duly served upon receipt as evidenced by the time shown in the transmission confirmation for the relevant documents.

 

16. 可分割性

 

Severability

 

如果本协议项下的任何条款因与有关法律不一致而无效或不可执行,则该条款仅在有关法律的管辖范围之内被视为无效或不可执行,并且本协议其他条款的有效性、合法性和可执行性不受其影响。

 

If any provision of this Agreement is judged to be invalid or unenforceable because it is inconsistent with applicable laws, such invalidity or unenforceability shall be only with respect to such laws, and the validity, legality and enforceability of the other provisions hereof shall not be affected.

 

15 / 30 

 

 

17. 文本

 

Counterparts

 

本协议由协议各方签署四(4)份原件,每方各执一(1)份,所有原件具有同等法律效力。本协议可以一份或多份副本形式签署。

 

This Agreement shall be executed in four (4) originals by all Parties, with each Party holding one original. All originals shall have the same legal effect. The Agreement may be executed in one or more counterparts.

 

18. 语言Languages

 

本协议英文和中文文本具有同等法律效力。英文和中文若有不一致,以中文文本为准。

 

Both Chinese and English versions of this Agreement shall have equal validity. In case of any discrepancy between the English version and the Chinese version, the Chinese version shall prevail.

  

[后附签字页Signature Pages Follow]

  

16 / 30 

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

  

北京众巢众行科技有限公司

 

Beijing Zhongchao Zhongxing Technology Co.,Ltd.

 

授权代表(Authorized Representative):/s/ Weiguang Yang

  

17 / 30 

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

 

众巢医学科技(上海)有限公司

 

Zhongchao Medical Technology (Shanghai) Co., Ltd.

 

授权代表(Authorized Representative):/s/ Weiguang Yang.

 

18 / 30 

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

 

杨伟光

 

Weiguang Yang

 

签字/Signature:/s/ Weiguang Yang.

 

19 / 30 

 

 

有鉴于此,各方于文首所述日期正式签署本协议。

 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement on the date appearing at the head hereof.

 

上海行众投资管理合伙企业(有限合伙)

 

Shanghai Xingzhong Investment Management LP, Ltd.

 

授权代表(Authorized Representative):/s/ Weiguang Yang.

 

20 / 30 

 

 

SCHEDULE 1

 

附件1

 

Shareholders

 

股东

 

序号   姓名   证件号码/统一信用代码
No.   Name   No.
1.   杨伟光   362227198206170314
    Weiguang Yang    
         
2.   上海行众投资管理合伙企业(有限合伙)   913101143584694449
    Shanghai Xingzhong Investment Management LP, Ltd.    

 

21 / 30 

 

 

SCHEDULE 2

 

附件2

 

股权转让协议

 

EQUITY INTEREST TRANSFER AGREEMENT

 

本股权转让协议(“本协议”)由以下各方于 年 月 日在上海订立:

  

This Equity Interest Transfer Agreement(this“Agreement”)is entered into in Shanghai as of , by and among the following parties: 

 

(1) 转让方(Transferor):

  

杨伟光,身份证号362227198206170314,为众巢医学科技(上海)有限公司(“众巢医学”)的股东;

 

Weiguang Yang, No. 362227198206170314, shareholder of Zhongchao Medical Technology (Shanghai) Co., Ltd.(“Zhongchao”) ;

 

上海行众投资管理合伙企业(有限合伙),统一信用代码913101143584694449,为众巢医学的股东;

 

Shanghai Xingzhong Investment Management LP, Ltd. , No. 913101143584694449, shareholder of Zhongchao;

  

(2)  受让方(Transferee):

  

北京众巢众行科技有限公司“外商独资企业”)一家根据中华人民共和国(“中国”)法律在中国上海注册成立的外商独资企业;

 

Beijing Zhongchao Zhongxing Technology Co.,Ltd. (the “WFOE”), a wholly foreign-owned enterprise registered in Shanghai, the People’s Republic of China (“China” or “PRC”), under the laws of China;

 

(3) 目标公司(Target Company):

 

众巢医学科技(上海)有限公司(“众巢医学”),一家根据中国法律在中国上海注册成立的内资公司;

 

Zhongchao Medical Technology (Shanghai) Co., Ltd. (“Zhongchao”), a domestic company registered in Shanghai, China, under the laws of China;

 

22 / 30 

 

 

每一位在上文列明的转让方单独称为 “一名股东”,合称为“股东”。

 

Each of the Transferors listed above (each, “a Shareholder” and collectively, the “Shareholders”).

 

(以上外商独资企业和每一位股东单独称为“一方”,合称为“各方”)。

 

(Each of the WFOE,each of the Shareholders, a “Party”, and collectively the “Parties”).

  

序言

 

RECITALS

 

(A) 鉴于,股东持有目标公司100%的股权;

 

WHEREAS, the Shareholders hold 100% equity interest in Target Company.

 

(B) 鉴于,转让方将其持有的目标公司         %股权转让予受让方,受让方同意根据本协议约定的条款和条件受让该股权。

 

WHEREAS, the Transferors desire to sell to Transferee         % of the equity interest in the Target Company, and Transferee desires to purchase from the Transferors according to the terms and expressions of this agreement;

 

23 / 30 

 

 

(C) 有鉴于此,基于本协议包含的各项前提、声明、保证、承诺和约定,各方愿意受其法律约束,并达成如下约定:

 

NOW, THEREFORE, in consideration of the premises and the representations, warranties, covenants and agreements herein contained, and intending to be legally bound hereby, the Parties hereby agree as follows:

 

协议

 

AGREEMENT

 

1. 转让标的

 

Transfer Target

 

本协议项下标的股权,是指本协议转让方持有的目标公司         %股权。

 

Target equity interest in this agreement refers to         % equity interest the transferer hold.

 

2. 股权转让

 

Equity Interest Transfer

 

2.1 转让方同意将其持有的标的股权及与该等股权相关的权益、利益及依法享有的全部权利转让予受让方。

 

The shareholders agree to transfer target equity interest, relevant rights and interests and all rights in accordance with law to the transferee.

 

2.2 受让方同意根据本协议约定的条款和条件受让标的股权及与该等股权相关的权益、利益及依法享有的全部权利。

 

According to the terms and requirement of this agreement, the transferee agree to acquire the target equity interest, relevant rights and interests and all rights in accordance with law to the transferee.

 

2.3 本次股权转让由受让方负责指派人员办理有关的工商变更登记手续,转让方负有配合义务。

 

For the purpose of the equity interest transfer, the transferee takes the responsible of arranging people to duel the transfer register precedures, the transferor have the obligation to cooperate.

 

24 / 30 

 

 

2.4 本协议各方一致同意,下述条件全部获得满足之日为本协议项下标的股权转让行为的完成日(下称“完成日”):

 

(1) 受让方已向转让方支付本协议第3条所述股权转让价款,目标公司更新股东名册,并向受让方颁发出资证明书;

 

(2) 目标公司就本次股权转让向工商行政管理部门办理并完成有关工商变更登记/备案手续。

 

Both parties of this agreement hereby agree to that the day of all the terms meet the requirement is called “closing day”, terms as follows:

 

(1) The transferee has already paid the transfer price according to Term 3 of this agreement, the target company has updated the shareholder list, and issued the certification of capital contribution to the transferee.

 

(2) The target company has already gone though the procedures of registering or filing at the industrial and commercial administrative department for this equity interest transfer.

 

2.5 自完成日起,受让方即享有和承担与标的股权有关的全部权利和义务,转让方则不再享有和承担与标的股权有关的任何权利和义务。

 

From the time of “closing day”, the transferee can enjoy and undertake all rights and obligations about the target equity interest, also the party of transfer cannot enjoy and undertake any other rights and obligations about the target equity interest.

 

3. 股权转让对价及支付

 

Payment of Transfer Price

 

本协议各方协商确定,本协议项下标的股权的转让对价为人民币               元(大写:               元)。该等对价为受让方取得标的股权所有权所需支付的全部款项。

 

According the agreement of both parties, the transfer price of the target equity interest is RMB                , the transferee should pay all the transfer price to aquire the stock rights.

 

25 / 30 

 

 

本协议各方一致同意,自完成标的股权相关的工商变更登记(登记在受让方名下) 之日起三十个工作日内,受让方向转让方付清股权转让价款。

 

Both parties of this agreement agree that the transferee should pay all the transfer price within thirty (30) working days ever since the day when the target equity interest registration has been registered (registered in the transferee).

 

4. 声明、承诺与保证

 

Representations、Promises and Warranties

 

转让方不可撤销地声明、保证及承诺如下:

 

The Transferor shall not revoke its representations, promises and warranties as follows:

 

4.1 转让方具有签署及履行本协议所必需的任何及所有民事权利能力和行为能力;且签署及履行本协议不会违反对其有约束力的任何及所有法律文件,包括但不限于公司章程、已签署的合同或协议等。

 

The transferor have any and all the authority to execute and perform this agreement; and the execution and performance of any obligations under this agreement do not cause any violation of any instruments to which they are a party or which are binding on them, including but not limited to articles of association, contacts or agreements which have be signed.

 

4.2 转让方已取得签订和履行本协议所需的一切同意、批准、授权和许可。

 

The transferor has obtained all the consent, approval, warrant, and permission for entering into and performance of this Agreement which is needed.

 

4.3 转让方对根据本协议向受让方转让之标的股权拥有合法、完整的所有权,且标的股权上不存在任何权利瑕疵和权利负担。

 

The transferor have legal and complete title to the target equity interest, and have not placed any security interest on the target equity interest.

 

受让方不可撤销地声明、保证及承诺如下:

 

The Transferee shall not revoke its representations, promises and warranties as follows:

 

26 / 30 

 

 

4.4 受让方具有签署及履行本协议所必需的任何及所有民事权利能力和行为能力;且 签署及履行本协议不会违反对其有约束力的任何及所有法律文件,包括但不限于公司章程、已签署的合同或协议等。

 

The transferee has any and all the authority to execute and perform this agreement; and the execution and performance of any obligations under this agreement do not cause any violation of any instruments to which they are a party or which are binding on them, including but not limited to articles of association, contacts or agreements which have be signed.

 

4.5 受让方已取得签订和履行本协议所需的一切同意、批准、授权和许可。

 

The transferee has obtained all the consent, approval, warrant, and permission for entering into and performance of this Agreement which is needed.

 

5. 违约责任

 

Default Responsibility

 

5.1 各方均应诚实、全面、适当履行本协议。

 

The parties should honestly, comprehensively, properly execute this agreement.

 

5.2 任何一方不履行或不完全履行本协议,给守约方造成损失的,应当赔偿守约方的全部损失。

 

Each party shall indemnify the observant part against any loss which such party shall incur as a consequence of fail to perform or incompletely perform this agreement.

 

6. 税费承担

 

Taxes and Fees

 

本协议各方一致同意,本协议所述之股权转让所涉及的有关税费分别由各方依据相关法律、法规及规范性文件自行承担。

 

Each party shall pay any transfer tax and fees incurred thereby or laced thereon in accordance with relevant laws, regulations and regulatory documents in connection with the equity interest transfer.

 

27 / 30 

 

 

7. 完整协议和协议的修改和解除

 

Entire Agreement and Amendment to Agreement

 

7.1 本协议及本协议中明确提及或包含的全部约定和/或文件构成有关本协议标的事项的完整约定,并取代此前各方就本协议标的事项达成的全部口头约定、合同、谅解和交流。

 

This Agreement and all agreements and/or documents mentioned or included explicitly by this Agreement constitute the complete agreement with respect to the subject matter of this Agreement and shall substitute any and all prior oral agreements, contracts, understandings and communications made by the Parties with respect to the subject matter of this Agreement.

 

7.2 本协议未尽事宜,各方将以书面签署补充协议的方式加以明确和说明,补充协议与本协议具有同等法律效力,若本协议与补充协议条款有冲突,则以补充协议为准。

 

If there is anything not involved in this agreement, all parties shall execute a supplementary agreement to clear and definite, which shall have the same legal effect as this agreement. If there is any conflict, the supplementary agreement shall prevail.

 

8. 保密

 

Confidentiality

 

8.1 各方承认,各方就本协议交换的任何口头或书面信息均属于保密信息。每一方应对上述全部信息保密,在未取得其他方的书面同意前,不得向任何第三方披露任何相关信息,但下述情况除外:(a)该信息已经或将被公众所知(但不是因为接受一方的违约披露导致的);(b)按照适用法律、法规或证券交易所的要求披露的;或(c)任何一方需要向其法律顾问、财务顾问、董事或高级管理人员披露的有关本协议项下拟定交易的信息,且该法律顾问、财务顾问、董事或高级管理 人员受与本款规定相类似的保密义务的制约。如任何一方聘用的任何职员或代理机构披露保密信息,将被视为该方披露了该保密信息并因此承担违约责任。本款规定将在本协议因任何原因终止后持续有效。

 

The Parties acknowledge that any oral or written information exchanged among them with respect to this Agreement is confidential information. Each Party shall maintain the confidentiality of all such information, and without obtaining the written consent of other Parties, it shall not disclose any relevant information to any third parties, except in the following circumstances: (a) such information is or will be in the public domain (provided that this is not the result of a public disclosure by the receiving party); (b) information disclosed as required by applicable laws or regulations or rules of any securities exchange; or (c) information required to be disclosed by any Party to its legal counsel, financial advisor, directors or senior management officers regarding the transaction contemplated hereunder, provided that such legal counsel, financial advisor, directors or senior management officers is also bound by confidentiality duties similar to the duties set out in this section. Disclosure of any confidential information by the staff members or agency hired by any Party shall be deemed disclosure of such confidential information by such Party, which Party shall be held liable for breach of this Agreement. This Section shall survive the termination of this Agreement for any reason.

 

8.2 各方同意本协议终止或失效时,本条仍然有效。

 

The Parties agree that this section shall remain survive the termination or expiration of this Agreement.

 

9. 不可抗力

 

Force Majeure

 

因不可抗力不能按照约定履行本协议的,根据不可抗力的影响,部分或全部免除责任,但因不可抗力不能按照约定履行协议的一方应当及时通知其他方,并采取必要和适当措施将不可抗力造成的损失降至最低。

 

If one party can’t perform this agreement due to force majeure, it shall be relieved of all or part of its obligations. The party that can’t perform this agreement should give prompt notification to other parties, and take necessary and appropriate measures to minimize the loss caused by force majeure.

 

28 / 30 

 

 

10. 管辖法律

 

Governing Law

 

本协议受中国法律管辖且据其进行解释。

 

This Agreement shall be construed in accordance with and governed by the laws of China.

 

11. 争议解决

 

Dispute Resolution

 

11.1 因本协议产生或与本协议相关的任何争议或主张应由各方通过友好协商的方式解决。如果各方未能解决争议,应将争议提交到上海国际经济贸易仲裁委员会(“仲裁委”),由仲裁委按照申请仲裁时有效的仲裁委仲裁规则经由仲裁解决。仲裁地为上海,仲裁语言为中文。只用一名仲裁员仲裁,该仲裁员由仲裁委指定。仲裁裁决具终局性且对各方都有约束力。

 

Any dispute or claim arising out of or in connection with or relating to this Agreement shall be resolved by the Parties in good faith through negotiations. In case no resolution can be reached by the Parties, such dispute shall be submitted to the Shanghai International Economic and Trade Arbitration Commission (the “Arbitration Commission”) for arbitration in accordance with its rules of arbitration in effect at the time of applying for such arbitration and the place of arbitration shall be in Shanghai, and the language of arbitration shall be Chinese. The arbitration tribunal shall be composed of only one arbitrator, which shall be appointed by the arbitration commission. The arbitral award shall be final and binding upon all Parties.

 

11.2 在争议解决和仲裁程序进行过程中,除了本协议正在仲裁的事宜以外,各方应在实际可行的前提下继续履行本协议。每一方应自行承担为解决任何争议而发生的费用,但仲裁费应由各方平均分担。

 

Throughout any dispute resolution and arbitration proceedings, the Parties shall continue to perform this Agreement, to the extent practical, with the exception of the matter that is under arbitration. Each Party shall be responsible for its own expenses in connection with resolving any Dispute, but the arbitration fees shall be shared equally.

 

12. 通知

 

Notices

 

任何一方按本协议规定发出的通知或其他通信应以英文或中文语书写,并可以专人递送、挂号邮寄、邮资预付邮寄、或受承认的专递服务或发送传真的形式发送到有关各方不时指定的收件地址。通知被视为实际到达的日期,应按如下方式确定:(a)专人递送的通知,专人递送当日即视为已实际送达;(b)用信函发出的通知,则在邮资付讫的航空挂号信寄出日(依邮戳为准)后的第十(10)天,即视为已实际送达,或在送交专递服务公司后的第四(4)天,即视为已实际送达;以及(c)用传真发送的通知,在有关文件的传送确认单上所显示的接收时间,即视为已实际送达。

 

Notices or other communications required to be given by any party pursuant to this Agreement shall be written in English and Chinese and delivered personally or sent by registered mail or postage prepaid mail or by a recognized courier service or by facsimile transmission to the address of each relevant party as specified by such party from time to time. The date when a notice is deemed to be duly served shall be determined as follows: (a) a notice delivered personally is deemed duly served upon delivery; (b) a notice sent by mail is deemed duly served on the tenth (10th) day after the date when the postage prepaid registered airmail is posted (as evidenced by the postmark), or on the fourth (4th) day after the date when the notice is delivered to an internationally-recognized courier service agency; and (c) a notice sent by facsimile transmission is deemed duly served upon receipt as evidenced by the time shown in the transmission confirmation for the relevant documents.

 

29 / 30 

 

 

13. 可分割性

 

Severability

 

果本协议项下的任何条款因与有关法律不一致而无效或不可执行,则该条款仅在有关法律的管辖范围之内被视为无效或不可执行,并且本协议其他条款的有效性,合法性和可强制执行性不受其影响。

 

If any provision of this Agreement is judged to be invalid or unenforceable because it is inconsistent with applicable laws, such invalidity or unenforceability shall be only with respect to such laws, and the validity, legality and enforceability of the other provisions hereof shall not be affected.

 

14. 文本

 

Counterparts

 

本协议由协议各方签署四(4)份原件,各方各执一(1)份,一份报相关部门,所有原件具有同等法律效力。

 

This Agreement shall be executed in four (4) originals by all Parties, with each Party holding one (1) original, the rest shall be submitted to relevant governmental departments. All originals shall have the same legal effect.

 

15. 语言

 

Languages

 

本协议的英文文本和中文文本具有同等法律效力。若英文文本和中文文本有任何不一致的约定,应以中文文本的相关内容为准。

 

Both Chinese and English versions of this Agreement shall have equal validity. In case of any discrepancy between the English version and the Chinese version, the Chinese version shall prevail.

 

 

30 / 30

 

 

Exhibit 10.6

 

VIE Confirmation Agreement

 

This VIE Confirmation Agreement(the “Agreement”)is entered into as of September 10, 2020 by and among the following parties:

 

1. Beijing Zhongchao Zhongxing Technology Co.,Ltd. (the WFOE”);
2. Zhongchao Medical Technology (Shanghai) Co., Ltd. (“Zhongchao”);
3. Each of the parties listed under Schedule (each, a “Shareholder” and collectively, the “Shareholders”)

 

WHEREAS, the WFOE, Zhongchao and Shareholders have entered into Business Cooperation Agreement, Exclusive Option Agreement, Equity Interest Pledge Agreement and Proxy Agreement and Power of Attorney dated August 14, 2019 (the “Original VIE Agreement”);

 

WHEREAS, Yantai Hanfujingfei Investment Centre (LP) no longer holds any shares of Zhongchao from December 2, 2019, and Xiangxiu Wang, Zhiheng Wang, Shanghai Haoxi Investment Management LP, Ltd., Ningbo Meishang Bonded Port Area Mijia Equity Investment LP, Ltd., Shenzhen Suiziyabo Equity Investment Centre (LP), Zhuhai Hengqinanci Culture Interconnection Equity Investment Fund LP, Ltd., Zhuhai Huyu Online Phase I Mobile Internet Investment Fund (LP), Zhuhai Henghui Investment LP, Ltd. and KAISA Jiayun Technology Inc. no longer hold any shares of Zhongchao from August 6, 2020;

 

Now the parties sign this Agreement to confirm the termination of the Original VIE Agreement, which shall be terminated when this Agreement is signed.

 

[No text below, Signature Pages Follow]

 

1 / 16

 

 

IN WITNESS WHEREOF, the Parties have duly executed this VIE Confirmation Agreement on the date appearing at the head hereof.

 

Beijing Zhongchao Zhongxing Technology Co., Ltd.

 

Company seal:/s/ Beijing Zhongchao Zhongxing Technology Co., Ltd.

 

2 / 16

 

 

IN WITNESS WHEREOF, the Parties have duly executed this VIE Confirmation Agreement on the date appearing at the head hereof.

 

Zhongchao Medical Technology (Shanghai) Co., Ltd.

 

Company seal: /s/ Zhongchao Medical Technology (Shanghai) Co., Ltd.

 

3 / 16

 

 

IN WITNESS WHEREOF, the Parties have duly executed this VIE Confirmation Agreement on the date appearing at the head hereof.

 

Weiguang Yang

 

Signature: /s/ Weiguang Yang.

 

4 / 16

 

 

IN WITNESS WHEREOF, the Parties have duly executed this VIE Confirmation Agreement on the date appearing at the head hereof.

 

Xiangxiu Wang

 

Signature: /s/ Xiangxiu Wang.

 

5 / 16

 

 

IN WITNESS WHEREOF, the Parties have duly executed this VIE Confirmation Agreement on the date appearing at the head hereof.

 

Zhiheng Wang

 

Signature: /s/ Zhiheng Wang.

 

6 / 16

 

 

IN WITNESS WHEREOF, the Parties have duly executed this VIE Confirmation Agreement on the date appearing at the head hereof.

 

Shanghai Xingzhong Investment Management LP, Ltd.

 

Company seal: /s/ Shanghai Xingzhong Investment Management LP, Ltd.

 

7 / 16

 

 

IN WITNESS WHEREOF, the Parties have duly executed this VIE Confirmation Agreement on the date appearing at the head hereof.

 

Shanghai Haoxi Investment Management LP, Ltd.

 

Company seal: /s/ Shanghai Haoxi Investment Management LP, Ltd.

 

8 / 16

 

 

IN WITNESS WHEREOF, the Parties have duly executed this VIE Confirmation Agreement on the date appearing at the head hereof.

 

Yantai Hanfujingfei Investment Centre (LP)

 

Company seal:/s/ Yantai Hanfujingfei Investment Centre (LP)

 

9 / 16

 

 

IN WITNESS WHEREOF, the Parties have duly executed this VIE Confirmation Agreement on the date appearing at the head hereof.

 

Ningbo Meishang Bonded Port Area Mijia Equity Investment LP, Ltd.

 

Company seal: /s/ Ningbo Meishang Bonded Port Area Mijia Equity Investment LP, Ltd.

 

10 / 16

 

 

IN WITNESS WHEREOF, the Parties have duly executed this VIE Confirmation Agreement on the date appearing at the head hereof.

 

Shenzhen Suiziyabo Equity Investment Centre (LP)

 

Company seal: /s/ Shenzhen Suiziyabo Equity Investment Centre (LP)

 

11 / 16

 

 

IN WITNESS WHEREOF, the Parties have duly executed this VIE Confirmation Agreement on the date appearing at the head hereof.

 

Zhuhai Hengqinanci Culture Interconnection Equity Investment Fund LP, Ltd.

 

Company seal: /s/ Zhuhai Hengqinanci Culture Interconnection Equity Investment Fund LP, Ltd.

 

12 / 16

 

 

IN WITNESS WHEREOF, the Parties have duly executed this VIE Confirmation Agreement on the date appearing at the head hereof.

 

Zhuhai Huyu Online Phase I Mobile Internet Investment Fund (LP)

 

Company seal: /s/ Zhuhai Huyu Online Phase I Mobile Internet Investment Fund (LP)

 

13 / 16

 

 

IN WITNESS WHEREOF, the Parties have duly executed this VIE Confirmation Agreement on the date appearing at the head hereof.

 

Zhuhai Henghui Investment LP, Ltd.

 

Company seal: /s/ Zhuhai Henghui Investment LP, Ltd.

 

14 / 16

 

 

IN WITNESS WHEREOF, the Parties have duly executed this VIE Confirmation Agreement on the date appearing at the head hereof.

 

KAISA Jiayun Technology Inc.

 

Company seal: /s/ KAISA Jiayun Technology Inc.

 

15 / 16

 

 

SCHEDULE

 

Shareholders

 

No.   Name   No.
         
1.   Weiguang Yang   362227198206170314
2.   Xiangxiu Wang   360202197402214042
3.   Zhiheng Wang   430104195903153010
4.   Shanghai Xingzhong Investment Management LP, Ltd.   913101143584694449
5.   Shanghai Haoxi Investment Management LP, Ltd.   91310114MA1GT02C24
6.   Yantai Hanfujingfei Investment Centre (LP)   91370600MA3CD6XA2D
7.   Ningbo Meishang Bonded Port Area Mijia Equity Investment LP, Ltd.   91330206MA2AEPGF97
8.   Shenzhen Suiziyabo Equity Investment Centre (LP)   91440300350028521M
9.   Zhuhai Hengqinanci Culture Interconnection Equity Investment Fund LP, Ltd.   91440400303818141B
10.   Zhuhai Huyu Online Phase I Mobile Internet Investment Fund (LP)   91440400334834574D
11.   Zhuhai Henghui Investment LP, Ltd.   914404003455413203
12.   KAISA Jiayun Technology Inc.   91441900738599734U

 

 

16 / 16